

# Fadlo R Khuri

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6529612/publications.pdf>

Version: 2024-02-01

602  
papers

62,768  
citations

1371

108  
h-index

1190

228  
g-index

631  
all docs

631  
docs citations

631  
times ranked

70631  
citing authors

#	ARTICLE	IF	CITATIONS
1	Systematic discovery of mutation-directed neo-protein-protein interactions in cancer. <i>Cell</i> , 2022, 185, 1974-1985.e12.	28.9	17
2	A Multicenter Randomized Phase II Study of Single Agent Efficacy and Optimal Combination Sequence of Everolimus and Pasireotide LAR in Advanced Thyroid Cancer. <i>Cancers</i> , 2022, 14, 2639.	3.7	4
3	YAP1 Expression in SCLC Defines a Distinct Subtype With T-cellâ€œInflamed Phenotype. <i>Journal of Thoracic Oncology</i> , 2021, 16, 464-476.	1.1	93
4	From Cancer to COVID, Boston to Beirut. <i>Cancer</i> , 2021, 127, 1172-1173.	4.1	2
5	Passing the baton. <i>Cancer</i> , 2021, 127, 1957-1958.	4.1	0
6	In Lebanon â€œIt Never Rains But It Poursâ€œ”How the American University of Beirut faced dangers and seized opportunities: Transforming medical education through multiple crises. <i>FASEB BioAdvances</i> , 2021, 3, 676-682.	2.4	2
7	The Beirut Port explosion: injury trends from a mass survey of emergency admissions. <i>Lancet</i> , The, 2021, 398, 21-22.	13.7	16
8	Locally advanced lung cancer. <i>Ca-A Cancer Journal for Clinicians</i> , 2021, 71, 461-465.	329.8	4
9	The National Cancer Act of 1971: A seminal milestone in the fight against cancer. <i>Cancer</i> , 2021, 127, 4532-4533.	4.1	4
10	Where it all began. <i>Cancer</i> , 2021, 127, 4541-4545.	4.1	0
11	Neoadjuvant chemotherapy and Avelumab in early stage resectable nonsmall cell lung cancer. <i>Cancer Medicine</i> , 2020, 9, 8406-8411.	2.8	31
12	Phase 1 safety and pharmacodynamic study of lenalidomide combined with everolimus in patients with advanced solid malignancies with efficacy signal in adenoid cystic carcinoma. <i>British Journal of Cancer</i> , 2020, 123, 1228-1234.	6.4	6
13	Progress in breast cancer research amid the COVIDâ€™19 gloom. <i>Cancer</i> , 2020, 126, 3809-3810.	4.1	0
14	Phase Ib Study of Chemoprevention with Green Tea Polyphenon E and Erlotinib in Patients with Advanced Premalignant Lesions (APL) of the Head and Neck. <i>Clinical Cancer Research</i> , 2020, 26, 5860-5868.	7.0	11
15	A Phase I Study of Safety, Pharmacokinetics, and Pharmacodynamics of Concurrent Everolimus and Buparlisib Treatment in Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2020, 26, 2497-2505.	7.0	9
16	Greetings from the front lines, when all the world is the front. <i>Cancer</i> , 2020, 126, 4105-4106.	4.1	1
17	Trimodality Therapy in the Treatment of Stage III N2â€Positive Nonâ€Small Cell Lung Cancer: A National Cancer Database Analysis. <i>Oncologist</i> , 2020, 25, e964-e975.	3.7	12
18	Rare tumors in China: A step in the right direction. <i>Cancer</i> , 2020, 126, 2047-2047.	4.1	0

#	ARTICLE	IF	CITATIONS
19	Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: a randomized phase II study. , 2020, 8, e001302.		34
20	Deep targeted sequencing analysis of hot spot mutations in non-small cell lung cancer patients from the Middle Eastern population. Journal of Thoracic Disease, 2019, 11, 2383-2391.	1.4	3
21	A very personal war. Cancer, 2019, 125, 2725-2727.	4.1	2
22	Survival Outcomes With Thoracic Radiotherapy in Extensive-Stage Small-Cell Lung Cancer: A Propensity Score-Matched Analysis of the National Cancer Database. Clinical Lung Cancer, 2019, 20, 484-493.e6.	2.6	16
23	Characteristics and Outcomes of Patients With Metastatic KRAS-Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium Experience. Journal of Thoracic Oncology, 2019, 14, 876-889.	1.1	141
24	Concurrent chemoradiotherapy with weekly versus triweekly cisplatin in locally advanced squamous cell carcinoma of the head and neck: Comparative analysis. Head and Neck, 2019, 41, 1490-1498.	2.0	21
25	The fork in the road: Waun Ki Hong, John Mendelsohn, and the reinvigoration of The University of Texas MD Anderson Cancer Center. Cancer, 2019, 125, 1593-1596.	4.1	0
26	Evaluation of preclinical efficacy of everolimus and pasireotide in thyroid cancer cell lines and xenograft models. PLoS ONE, 2019, 14, e0206309.	2.5	7
27	Editor's Note: Identification of Insulin-Like Growth Factor Binding Protein-3 as a Farnesyl Transferase Inhibitor SCH66336-Induced Negative Regulator of Angiogenesis in Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research, 2019, 25, 4861-4861.	7.0	0
28	A randomized phase II study of tremelimumab and durvalumab with or without radiation for patients with relapsed small cell lung cancer (SCLC).. Journal of Clinical Oncology, 2019, 37, 8515-8515.	1.6	6
29	Phase 1b study of chemoprevention with green tea polyphenon E (PPE) and epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (Erlotinib) in patients (pts) with advanced premalignant (AP) lesions of the head and neck.. Journal of Clinical Oncology, 2019, 37, 6049-6049.	1.6	0
30	An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. Cell, 2018, 173, 400-416.e11.	28.9	2,277
31	Comprehensive Characterization of Cancer Driver Genes and Mutations. Cell, 2018, 173, 371-385.e18.	28.9	1,670
32	Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer. Cell, 2018, 173, 291-304.e6.	28.9	1,718
33	A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples. Cell, 2018, 173, 386-399.e12.	28.9	228
34	Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics. Cell, 2018, 173, 305-320.e10.	28.9	272
35	Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation. Cell, 2018, 173, 338-354.e15.	28.9	1,417
36	Oncogenic Signaling Pathways in The Cancer Genome Atlas. Cell, 2018, 173, 321-337.e10.	28.9	2,111

#	ARTICLE	IF	CITATIONS
37	Pathogenic Germline Variants in 10,389 Adult Cancers. <i>Cell</i> , 2018, 173, 355-370.e14.	28.9	620
38	Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types. <i>Cell Reports</i> , 2018, 23, 282-296.e4.	6.4	333
39	Driver Fusions and Their Implications in the Development and Treatment of Human Cancers. <i>Cell Reports</i> , 2018, 23, 227-238.e3.	6.4	407
40	Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas. <i>Cell Reports</i> , 2018, 23, 194-212.e6.	6.4	245
41	Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context. <i>Cell Reports</i> , 2018, 23, 297-312.e12.	6.4	205
42	The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. <i>Cell Reports</i> , 2018, 23, 313-326.e5.	6.4	523
43	Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images. <i>Cell Reports</i> , 2018, 23, 181-193.e7.	6.4	683
44	The Immune Landscape of Cancer. <i>Immunity</i> , 2018, 48, 812-830.e14.	14.3	3,706
45	Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas. <i>Cell Reports</i> , 2018, 23, 172-180.e3.	6.4	119
46	Integrated Genomic Analysis of the Ubiquitin Pathway across Cancer Types. <i>Cell Reports</i> , 2018, 23, 213-226.e3.	6.4	83
47	Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas. <i>Cell Reports</i> , 2018, 23, 239-254.e6.	6.4	801
48	Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers. <i>Cell Reports</i> , 2018, 23, 255-269.e4.	6.4	204
49	Systematic Analysis of Splice-Site-Creating Mutations in Cancer. <i>Cell Reports</i> , 2018, 23, 270-281.e3.	6.4	177
50	The OncoPPI Portal: an integrative resource to explore and prioritize protein-protein interactions for cancer target discovery. <i>Bioinformatics</i> , 2018, 34, 1183-1191.	4.1	41
51	Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines. <i>Cell Systems</i> , 2018, 6, 271-281.e7.	6.2	605
52	Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas. <i>Cell Systems</i> , 2018, 6, 282-300.e2.	6.2	284
53	lncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic lncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in Cancer. <i>Cancer Cell</i> , 2018, 33, 706-720.e9.	16.8	400
54	Genomic and Functional Approaches to Understanding Cancer Aneuploidy. <i>Cancer Cell</i> , 2018, 33, 676-689.e3.	16.8	750

#	ARTICLE	IF	CITATIONS
55	Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas. <i>Cancer Cell</i> , 2018, 33, 721-735.e8.	16.8	396
56	A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. <i>Cancer Cell</i> , 2018, 33, 690-705.e9.	16.8	478
57	The Dietary Supplement Chondroitin-4-Sulfate Exhibits Oncogene-Specific Pro-tumor Effects on BRAF V600E Melanoma Cells. <i>Molecular Cell</i> , 2018, 69, 923-937.e8.	9.7	12
58	Comparison of the toxicity profile of PD&#x2011; versus PD&#x2011; inhibitors in non&#x2011;small cell lung cancer: A systematic analysis of the literature. <i>Cancer</i> , 2018, 124, 271-277.	4.1	265
59	The PLAG1-GDH1 Axis Promotes Anoikis Resistance and Tumor Metastasis through CamKK2-AMPK Signaling in LKB1-Deficient Lung Cancer. <i>Molecular Cell</i> , 2018, 69, 87-99.e7.	9.7	217
60	A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF-Î² Superfamily. <i>Cell Systems</i> , 2018, 7, 422-437.e7.	6.2	134
61	Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer. <i>Cell Reports</i> , 2018, 25, 1304-1317.e5.	6.4	329
62	On the humane side of medicine. <i>Cancer</i> , 2018, 124, 3969-3970.	4.1	0
63	Inhibition of IGF1R enhances 2-deoxyglucose in the treatment of non-small cell lung cancer. <i>Lung Cancer</i> , 2018, 123, 36-43.	2.0	11
64	Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients. <i>Cancer Cell</i> , 2018, 34, 211-224.e6.	16.8	623
65	MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring cRaf-Independent MEK Activation. <i>Cancer Cell</i> , 2018, 34, 315-330.e7.	16.8	94
66	HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models. <i>Clinical Cancer Research</i> , 2017, 23, 677-686.	7.0	58
67	Targeting 6-phosphogluconate dehydrogenase in the oxidative PPP sensitizes leukemia cells to antimalarial agent dihydroartemisinin. <i>Oncogene</i> , 2017, 36, 254-262.	5.9	53
68	Prevention of Dietary-Fat-Fueled Ketogenesis Attenuates BRAF V600E Tumor Growth. <i>Cell Metabolism</i> , 2017, 25, 358-373.	16.2	109
69	AKT1, LKB1, and YAP1 Revealed as MYC Interactors with NanoLuc-Based Protein-Fragment Complementation Assay. <i>Molecular Pharmacology</i> , 2017, 91, 339-347.	2.3	27
70	Phosphorylation-mediated activation of LDHA promotes cancer cell invasion and tumour metastasis. <i>Oncogene</i> , 2017, 36, 3797-3806.	5.9	190
71	The OncoPPi network of cancer-focused protein&#x2011;protein interactions to inform biological insights and therapeutic strategies. <i>Nature Communications</i> , 2017, 8, 14356.	12.8	151
72	HMG-CoA synthase 1 is a synthetic lethal partner of BRAFV600E in human cancers. <i>Journal of Biological Chemistry</i> , 2017, 292, 10142-10152.	3.4	28

#	ARTICLE	IF	CITATIONS
73	Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1â€targeted therapy in lung cancer patients. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 4993-4998.	7.1	614
74	OncoPPI-informed discovery of mitogen-activated protein kinase kinase 3 as a novel binding partner of c-Myc. Oncogene, 2017, 36, 5852-5860.	5.9	28
75	Modulation of Bax and mTOR for Cancer Therapeutics. Cancer Research, 2017, 77, 3001-3012.	0.9	24
76	Pulmonary Sarcomatoid Carcinoma: An Analysis of the National Cancer Data Base. Clinical Lung Cancer, 2017, 18, 286-292.	2.6	64
77	Association of Cytoplasmic CXCR4 With Loss of Epithelial Marker and Activation of ERK1/2 and AKT Signaling Pathways in Nonâ€Small-Cell Lung Cancer. Clinical Lung Cancer, 2017, 18, e203-e210.	2.6	14
78	Integrated genomic characterization of oesophageal carcinoma. Nature, 2017, 541, 169-175.	27.8	1,448
79	Comparison of Concurrent Use of Thoracic Radiation With Either Carboplatin-Paclitaxel or Cisplatin-Etoposide for Patients With Stage III Nonâ€Small-Cell Lung Cancer. JAMA Oncology, 2017, 3, 1120.	7.1	93
80	The known unknown. Cancer, 2017, 123, 17-19.	4.1	2
81	Gene Methylation Biomarkers in Sputum and Plasma as Predictors for Lung Cancer Recurrence. Cancer Prevention Research, 2017, 10, 635-640.	1.5	17
82	HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium. Cancer, 2017, 123, 4099-4105.	4.1	132
83	Five more years! Not everything changes. Cancer, 2017, 123, 724-727.	4.1	0
84	A better angel of our nature: Hannelore J. Kricheldorf • Kricheldorf M. D. (April 24, 1967â€May 22, 2017). Cancer, 2017, 123, 2998-3002.	4.1	0
85	California dreaming. Cancer, 2017, 123, 4528-4529.	4.1	0
86	National Cancer Database Analysis of Proton Versus Photon Radiation Therapy in Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2017, 97, 128-137.	0.8	105
87	P3.13-027 Utilization of PET Scan in Advanced Stage Non-Small Cell Lung Cancer in the United States. Journal of Thoracic Oncology, 2017, 12, S2325-S2326.	1.1	0
88	Targeting adhesion signaling in KRAS, LKB1 mutant lung adenocarcinoma. JCI Insight, 2017, 2, e90487.	5.0	36
89	Characteristics and outcomes of patients (pts) with metastatic KRAS mutant lung adenocarcinomas: Lung Cancer Mutation Consortium (LCMC) database.. Journal of Clinical Oncology, 2017, 35, 9021-9021.	1.6	15
90	MEDICI: Mining Essentiality Data to Identify Critical Interactions for Cancer Drug Target Discovery and Development. PLoS ONE, 2017, 12, e0170339.	2.5	4

#	ARTICLE	IF	CITATIONS
91	Gene methylation biomarkers in sputum as a classifier for lung cancer risk. Oncotarget, 2017, 8, 63978-63985.	1.8	19
92	Phenformin enhances the therapeutic effect of selumetinib in KRAS-mutant non-small cell lung cancer irrespective of LKB1 status. Oncotarget, 2017, 8, 59008-59022.	1.8	11
93	Survival outcomes in extensive stage small cell lung cancer patients treated with thoracic radiation.. Journal of Clinical Oncology, 2017, 35, 8565-8565.	1.6	0
94	Early proliferation of PD-1+ CD8 T cells in peripheral blood as predictive of response to PD-1 inhibition for patients with advanced NSCLC.. Journal of Clinical Oncology, 2017, 35, e20648-e20648.	1.6	0
95	Optimal thoracic radiation dose in limited stage small cell lung cancer.. Journal of Clinical Oncology, 2017, 35, 8562-8562.	1.6	0
96	Abstract 2333: Modulation of Bax and mTOR for cancer therapeutics. , 2017, , .		0
97	Abstract 3261: Gene methylation biomarkers in sputum as a classifier for lung cancer risk. , 2017, , .		0
98	Perspective on the National Comprehensive Cancer Network's Clinical Practice Guidelines for Smoking Cessation. Journal of Oncology Practice, 2016, 12, 55-58.	2.5	11
99	Clinical outcomes in elderly patients with human papillomavirusâ€“positive squamous cell carcinoma of the oropharynx treated with definitive chemoradiation therapy. Head and Neck, 2016, 38, 846-851.	2.0	15
100	RSK2 signals through stathmin to promote microtubule dynamics and tumor metastasis. Oncogene, 2016, 35, 5412-5421.	5.9	22
101	Lung Adenocarcinoma Staging Using the 2011 IASLC/ATS/ERS Classification: A Pooled Analysis of Adenocarcinoma In Situ and Minimally Invasive Adenocarcinoma. Clinical Lung Cancer, 2016, 17, e57-e64.	2.6	68
102	Patient-derived xenografts faithfully replicated clinical outcome in a phase II co-clinical trial of arsenic trioxide in relapsed small cell lung cancer. Journal of Translational Medicine, 2016, 14, 111.	4.4	78
103	Transforming Big Data into Cancer-Relevant Insight: An Initial, Multi-Tier Approach to Assess Reproducibility and Relevance. Molecular Cancer Research, 2016, 14, 675-682.	3.4	11
104	Tetrameric Acetyl-CoA Acetyltransferase 1 Is Important for Tumor Growth. Molecular Cell, 2016, 64, 859-874.	9.7	73
105	Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium. Cancer, 2016, 122, 766-772.	4.1	92
106	Clinical Validation and Implementation of a Targeted Next-Generation Sequencing Assay to Detect Somatic Variants in Non-Small Cell Lung, Melanoma, and Gastrointestinal Malignancies. Journal of Molecular Diagnostics, 2016, 18, 299-315.	2.8	55
107	Enabling systematic interrogation of proteinâ€“protein interactions in live cells with a versatile ultra-high-throughput biosensor platform. Journal of Molecular Cell Biology, 2016, 8, 271-281.	3.3	27
108	Preclinical <i>In Vitro</i>, <i>In Vivo</i>, and Pharmacokinetic Evaluations of FLLL12 for the Prevention and Treatment of Head and Neck Cancers. Cancer Prevention Research, 2016, 9, 63-73.	1.5	9

#	ARTICLE	IF	CITATIONS
109	Mannitol to prevent cisplatin-induced nephrotoxicity in patients with squamous cell cancer of the head and neck (SCCHN) receiving concurrent therapy. Supportive Care in Cancer, 2016, 24, 1789-1793.	2.2	34
110	Trends, predictors, and impact of systemic chemotherapy in small cell lung cancer patients between 1985 and 2005. Cancer, 2016, 122, 50-60.	4.1	37
111	Inhibition of mTOR complex 2 induces GSK3/FBXW7-dependent degradation of sterol regulatory element-binding protein 1 (SREBP1) and suppresses lipogenesis in cancer cells. Oncogene, 2016, 35, 642-650.	5.9	60
112	Inhibition of B-Raf/MEK/ERK signaling suppresses DR5 expression and impairs response of cancer cells to DR5-mediated apoptosis and T cell-induced killing. Oncogene, 2016, 35, 459-467.	5.9	11
113	Evaluation of toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2016, 34, 9035-9035.	1.6	5
114	LKB1 promotes cell survival by modulating TIF-IA-mediated pre-ribosomal RNA synthesis under uridine downregulated conditions. Oncotarget, 2016, 7, 2519-2531.	1.8	7
115	Diagnosis and Multidisciplinary Treatment of Laryngeal Cancers. , 2016, , 555-567.		0
116	Abstract B15: RSK2 signals through stathmin to promote microtubule dynamics and tumor metastasis. , 2016, , .		0
117	Abstract B45: An early treatment window to target FAK-dependent collective invasion in Lkb1-mutant lung adenocarcinoma. , 2016, , .		0
118	National Cancer Data Base analysis of proton versus photon radiotherapy in non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2016, 34, 8501-8501.	1.6	0
119	Non-small cell lung cancer (NSCLC) as a second primary: Analysis of the National Cancer Data Base (NCDB).. Journal of Clinical Oncology, 2016, 34, e20022-e20022.	1.6	0
120	Abstract LB-348: Developing a personalized anti-metastatic therapy to treat KRAS, LKB1-mutant lung adenocarcinoma. , 2016, , .		0
121	Abstract 4770: The regulation of pre-ribosomal RNA synthesis by LKB1. , 2016, , .		0
122	Abstract 1866: HER3 targeting sensitizes HNSCC to cetuximab - evidence from cell line and patient derived xenograft (PDX) models. , 2016, , .		0
123	Time to divest from tobacco-funded research. Cancer, 2015, 121, 2294-2295.	4.1	1
124	Lung cancer in China: The new frontier?. Cancer, 2015, 121, 3058-3060.	4.1	1
125	An overview of <i>Cancer's</i> special issue on lung cancer in China. Cancer, 2015, 121, 3049-3051.	4.1	1
126	Tobacco and China: The worst is yet to come. Cancer, 2015, 121, 3052-3054.	4.1	5



#	ARTICLE	IF	CITATIONS
127	Early detection of lung cancer in China: The immediate imperative. <i>Cancer</i> , 2015, 121, 3055-3057.	4.1	1
128	Bevacizumab in Combination with Taxane versus Non-Taxane Containing Regimens for Advanced/Metastatic Nonsquamous Non-Small-Cell Lung Cancer: A Systematic Review. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1142-1147.	1.1	19
129	Pain Intensity and Pain Interference in Patients With Lung Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015, 38, 457-464.	1.3	6
130	Business as usual is not acceptable. <i>Cancer</i> , 2015, 121, 2864-2865.	4.1	3
131	Development and testing of a tool to assess patient preferences for phase I clinical trial participation. <i>Psycho-Oncology</i> , 2015, 24, 835-838.	2.3	6
132	Heregulin and HER3 are prognostic biomarkers in oropharyngeal squamous cell carcinoma. <i>Cancer</i> , 2015, 121, 3600-3611.	4.1	44
133	Curcumin Induces Apoptosis of Upper Aerodigestive Tract Cancer Cells by Targeting Multiple Pathways. <i>PLoS ONE</i> , 2015, 10, e0124218.	2.5	34
134	GSK3 is required for rapalogs to induce degradation of some oncogenic proteins and to suppress cancer cell growth. <i>Oncotarget</i> , 2015, 6, 8974-8987.	1.8	15
135	Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy. <i>Cancer Cell</i> , 2015, 27, 852-863.	16.8	108
136	Enhancing therapeutic efficacy of the MEK inhibitor, MEK162, by blocking autophagy or inhibiting PI3K/Akt signaling in human lung cancer cells. <i>Cancer Letters</i> , 2015, 364, 70-78.	7.2	40
137	A Titan exits stage left: Summary of the Waun Ki Hong Festschrift. <i>Cancer</i> , 2015, 121, 2849-2851.	4.1	1
138	A Translational, Pharmacodynamic, and Pharmacokinetic Phase IB Clinical Study of Everolimus in Resectable Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 1859-1868.	7.0	22
139	Glutamate Dehydrogenase 1 Signals through Antioxidant Glutathione Peroxidase 1 to Regulate Redox Homeostasis and Tumor Growth. <i>Cancer Cell</i> , 2015, 27, 257-270.	16.8	269
140	The next generation of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of lung cancer. <i>Cancer</i> , 2015, 121, E1-6.	4.1	55
141	Genomic Classification of Cutaneous Melanoma. <i>Cell</i> , 2015, 161, 1681-1696.	28.9	2,562
142	Racial disparities in squamous cell carcinoma of the oral tongue among women: A SEER data analysis. <i>Oral Oncology</i> , 2015, 51, 586-592.	1.5	43
143	In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. <i>Mayo Clinic Proceedings</i> , 2015, 90, 996-1000.	3.0	128
144	Metabolic Rewiring by Oncogenic BRAF V600E Links Ketogenesis Pathway to BRAF-MEK1 Signaling. <i>Molecular Cell</i> , 2015, 59, 345-358.	9.7	125

#	ARTICLE	IF	CITATIONS
145	Dose escalation with over-dose and under-dose controls in Phase I/II clinical trials. Contemporary Clinical Trials, 2015, 43, 133-141.	1.8	16
146	Rictor Undergoes Glycogen Synthase Kinase 3 (GSK3)-dependent, FBXW7-mediated Ubiquitination and Proteasomal Degradation. Journal of Biological Chemistry, 2015, 290, 14120-14129.	3.4	59
147	Re-expression of LKB1 in LKB1-mutant EKVX cells leads to resistance to paclitaxel through the up-regulation of MDR1 expression. Lung Cancer, 2015, 88, 131-138.	2.0	11
148	FLL12 induces apoptosis in lung cancer cells through a p53/p73-independent but death receptor 5-dependent pathway. Cancer Letters, 2015, 363, 166-175.	7.2	13
149	Predictors and outcomes of venous thromboembolism in hospitalized lung cancer patients: A Nationwide Inpatient Sample database analysis. Lung Cancer, 2015, 88, 80-84.	2.0	22
150	Combination of erlotinib and EGCG induces apoptosis of head and neck cancers through posttranscriptional regulation of Bim and Bcl-2. Apoptosis: an International Journal on Programmed Cell Death, 2015, 20, 986-995.	4.9	26
151	Anaplastic lymphoma kinase (ALK) gene alteration in signet ring cell carcinoma of the gastrointestinal tract. Therapeutic Advances in Medical Oncology, 2015, 7, 56-62.	3.2	18
152	Can we achieve an 80% screening rate for colorectal cancer by 2018 in the United States?. Cancer, 2015, 121, 2127-2128.	4.1	10
153	mTOR Complex 2 Stabilizes Mcl-1 Protein by Suppressing Its Glycogen Synthase Kinase 3-Dependent and SCF-FBXW7-Mediated Degradation. Molecular and Cellular Biology, 2015, 35, 2344-2355.	2.3	48
154	Atypical Carcinoid Tumor of the Lung: A Surveillance, Epidemiology, and End Results Database Analysis. Journal of Thoracic Oncology, 2015, 10, 479-485.	1.1	63
155	Postoperative Radiotherapy is Associated with Better Survival in Non-Small Cell Lung Cancer with Involved N2 Lymph Nodes: Results of an Analysis of the National Cancer Data Base. Journal of Thoracic Oncology, 2015, 10, 462-471.	1.1	101
156	6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling. Nature Cell Biology, 2015, 17, 1484-1496.	10.3	224
157	Necitumumab in Metastatic Squamous Cell Lung Cancer. JAMA Oncology, 2015, 1, 1293.	7.1	43
158	A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1). Annals of Oncology, 2015, 26, 1741-1748.	1.2	87
159	Modernizing Eligibility Criteria for Molecularly Driven Trials. Journal of Clinical Oncology, 2015, 33, 2815-2820.	1.6	80
160	What we know and what we think we know: An editor's perspective on a charged debate. Cancer, 2015, 121, 4-5.	4.1	2
161	Cables1 Complex Couples Survival Signaling to the Cell Death Machinery. Cancer Research, 2015, 75, 147-158.	0.9	35
162	Cables1 controls p21/Cip1 protein stability by antagonizing proteasome subunit alpha type 3. Oncogene, 2015, 34, 2538-2545.	5.9	42

#	ARTICLE	IF	CITATIONS
163	Abstract 1317: Biomarker evaluation for PD-1 targeted therapies in non-small cell lung cancer (NSCLC) patients. Cancer Research, 2015, 75, 1317-1317.	0.9	1
164	Concurrent chemoradiation using weekly versus tri-weekly cisplatin in locally advanced squamous cell carcinoma of the head and neck (SCCHN): A comparative analysis.. Journal of Clinical Oncology, 2015, 33, 6055-6055.	1.6	3
165	Dual targeting of EGFR and HER3 with cetuximab and MM-121/SAR256212 in HNSCC patient derived xenograft (PDX) models.. Journal of Clinical Oncology, 2015, 33, e17066-e17066.	1.6	1
166	Combination of heat shock protein 90 and focal adhesion kinase inhibitors synergistically inhibits the growth of non-small cell lung cancer cells. Oncoscience, 2015, 2, 765-776.	2.2	12
167	The novel proteasome inhibitor carfilzomib activates and enhances extrinsic apoptosis involving stabilization of death receptor 5. Oncotarget, 2015, 6, 17532-17542.	1.8	38
168	Small molecule inhibition of the CHFR-PARP1 interaction as novel approach to overcome intrinsic taxane resistance in cancer. Oncotarget, 2015, 6, 30773-30786.	1.8	17
169	The BET bromodomain inhibitor, JQ1, facilitates c-FLIP degradation and enhances TRAIL-induced apoptosis independent of BRD4 and c-Myc inhibition. Oncotarget, 2015, 6, 34669-34679.	1.8	35
170	Suppression of death receptor 5 enhances cancer cell invasion and metastasis through activation of caspase-8/TRAF2-mediated signaling. Oncotarget, 2015, 6, 41324-41338.	1.8	28
171	Landscape of genetic alterations in non-smoking patients with oral tongue carcinoma: An analysis of The Cancer Genome Atlas (TCGA) head and neck squamous cell carcinoma data.. Journal of Clinical Oncology, 2015, 33, 6073-6073.	1.6	0
172	Necitumumab in metastatic squamous non-small cell lung cancer (mSqNSCLC): Establishing a value-based cost.. Journal of Clinical Oncology, 2015, 33, 6505-6505.	1.6	1
173	Abstract 29: Potent curcumin analog FLLL12 induces apoptosis in lung cancer cells through death receptor-5-dependent pathway. , 2015, , .		0
174	Abstract 2922: Development of Bcl2 BH4 antagonist for cancer therapy. , 2015, , .		0
175	Abstract CT303: A phase I pharmacokinetic and pharmacodynamic evaluation of the combination of everolimus and buparlisib for concurrent mTOR and PI3K pathway blockade in patients with advanced solid tumors. , 2015, , .		0
176	Abstract 3046: Glutamate dehydrogenase 1 signals through antioxidant glutathione peroxidase 1 to regulate redox homeostasis and tumor growth. Cancer Research, 2015, 75, 3046-3046.	0.9	1
177	Transcriptional Regulation of YWHAZ, the Gene Encoding 14-3-3 $\uparrow$ . PLoS ONE, 2014, 9, e93480.	2.5	17
178	Aberrant Promoter Methylation of Caveolin-1 Is Associated with Favorable Response to Taxane-Platinum Combination Chemotherapy in Advanced NSCLC. PLoS ONE, 2014, 9, e107124.	2.5	21
179	Phase 1 and pharmacokinetic study of everolimus in combination with cetuximab and carboplatin for recurrent/metastatic squamous cell carcinoma of the head and neck. Cancer, 2014, 120, 3940-3951.	4.1	53
180	Tyr-301 Phosphorylation Inhibits Pyruvate Dehydrogenase by Blocking Substrate Binding and Promotes the Warburg Effect. Journal of Biological Chemistry, 2014, 289, 26533-26541.	3.4	61

#	ARTICLE	IF	CITATIONS
181	Poly (<scp>ADP</scp>) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer. Cancer Medicine, 2014, 3, 1579-1594.	2.8	74
182	AACR Celebrates 50 Years of Tobacco Research and Policy. Clinical Cancer Research, 2014, 20, 1709-1718.	7.0	0
183	Integrated Genomic Characterization of Papillary Thyroid Carcinoma. Cell, 2014, 159, 676-690.	28.9	2,318
184	A phase 2 trial of dacomitinib (PF&#00299804), an oral, irreversible pan&#HER (human epidermal growth) Tj ETQq0 0 0 rgBT /Overlock 1 prior chemotherapy and erlotinib. Cancer, 2014, 120, 1145-1154.	4.1	125
185	Of Gdansk and glass houses. Cancer, 2014, 120, 612-613.	4.1	0
186	Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs. JAMA - Journal of the American Medical Association, 2014, 311, 1998.	7.4	1,386
187	Tyr-94 Phosphorylation Inhibits Pyruvate Dehydrogenase Phosphatase 1 and Promotes Tumor Growth. Journal of Biological Chemistry, 2014, 289, 21413-21422.	3.4	50
188	Chemoprevention of Head and Neck Cancer with Celecoxib and Erlotinib: Results of a Phase Ib and Pharmacokinetic Study. Cancer Prevention Research, 2014, 7, 283-291.	1.5	62
189	Randomized Safety and Efficacy Study of Foscarnet with Paclitaxel/Carboplatin Against Anaplastic Thyroid Carcinoma. Thyroid, 2014, 24, 232-240.	4.5	130
190	Acetylated Tubulin (AT) as a Prognostic Marker in Squamous Cell Carcinoma of the Head and Neck. Head and Neck Pathology, 2014, 8, 66-72.	2.6	34
191	Altered Glutamine Metabolism and Therapeutic Opportunities for Lung Cancer. Clinical Lung Cancer, 2014, 15, 7-15.	2.6	88
192	Tyr Phosphorylation of PDP1 Toggles Recruitment between ACAT1 and SIRT3 to Regulate the Pyruvate Dehydrogenase Complex. Molecular Cell, 2014, 53, 534-548.	9.7	247
193	Escalation with overdose control using all toxicities and time to event toxicity data in cancer Phase I clinical trials. Contemporary Clinical Trials, 2014, 37, 322-332.	1.8	10
194	Targeted therapies in metastatic esophageal cancer: Advances over the past decade. Critical Reviews in Oncology/Hematology, 2014, 91, 186-196.	4.4	32
195	Evaluation of Hospitalization Trends in Lung Cancer Patients With Hyponatremia. International Journal of Radiation Oncology Biology Physics, 2014, 90, S62.	0.8	0
196	Clinical and Pathologic Characterization of Folate Receptor Alpha, Mesothelin, and Endosialin Expression in Mesotheliomas. International Journal of Radiation Oncology Biology Physics, 2014, 90, S29.	0.8	0
197	Higher Dose of Palliative Thoracic Radiation Is Associated With Improved Survival for Patients With Stage IV Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2014, 90, S48.	0.8	0
198	A Comparison of Palliative Inpatient Management Strategies for Cancer-Related Superior Vena Cava Obstruction. International Journal of Radiation Oncology Biology Physics, 2014, 90, S68-S69.	0.8	0

#	ARTICLE	IF	CITATIONS
199	Investigating the Molecular Profile of Lung Adenocarcinoma: A Single-Institution Analysis. International Journal of Radiation Oncology Biology Physics, 2014, 90, S50-S51.	0.8	0
200	Postoperative Radiation Therapy (PORT) Is Associated With Better Survival in Non-Small Cell Lung Cancer With Involved N2 Lymph Nodes. International Journal of Radiation Oncology Biology Physics, 2014, 90, S18.	0.8	0
201	Lung Adenocarcinoma Staging Based on 2011 IASLC/ATS/ERS Classification: A Pooled Analysis of Adenocarcinoma In Situ (AIS) and Minimally Invasive Adenocarcinoma (MIA). International Journal of Radiation Oncology Biology Physics, 2014, 90, S10.	0.8	0
202	HPV-associated lung cancers: an international pooled analysis. Carcinogenesis, 2014, 35, 1267-1275.	2.8	57
203	A Comparison of Palliative Inpatient Management Strategies for Cancer-Related Superior Vena Cava Obstruction. International Journal of Radiation Oncology Biology Physics, 2014, 90, S80-S81.	0.8	0
204	Class I HDACs Are Mediators of Smoke Carcinogenâ€“Induced Stabilization of DNMT1 and Serve as Promising Targets for Chemoprevention of Lung Cancer. Cancer Prevention Research, 2014, 7, 351-361.	1.5	38
205	Concurrent therapy with taxane versus non-taxane containing regimens in locally advanced squamous cell carcinomas of the head and neck (SCCHN): A systematic review. Oral Oncology, 2014, 50, 888-894.	1.5	20
206	Lysine Acetylation Activates 6-Phosphogluconate Dehydrogenase to Promote Tumor Growth. Molecular Cell, 2014, 55, 552-565.	9.7	107
207	Small-molecule Bax agonists for cancer therapy. Nature Communications, 2014, 5, 4935.	12.8	110
208	Role of Ku70 in deubiquitination of Mcl-1 and suppression of apoptosis. Cell Death and Differentiation, 2014, 21, 1160-1169.	11.2	58
209	Maintaining Glycogen Synthase Kinase-3 Activity Is Critical for mTOR Kinase Inhibitors to Inhibit Cancer Cell Growth. Cancer Research, 2014, 74, 2555-2568.	0.9	40
210	Long-term use of valproic acid in US veterans is associated with a reduced risk of smoking-related cases of head and neck cancer. Cancer, 2014, 120, 1394-1400.	4.1	27
211	The first surgeon general's report on smoking and health: The 50th anniversary. Ca-A Cancer Journal for Clinicians, 2014, 64, 5-8.	329.8	27
212	Second-Generation ALK Inhibitors: Filling the Non â€œMETâ€•Gap. Cancer Discovery, 2014, 4, 634-636.	9.4	8
213	Bcl2 Induces DNA Replication Stress by Inhibiting Ribonucleotide Reductase. Cancer Research, 2014, 74, 212-223.	0.9	40
214	Combination of Anti-HER3 Antibody MM-121/SAR256212 and Cetuximab Inhibits Tumor Growth in Preclinical Models of Head and Neck Squamous Cell Carcinoma. Molecular Cancer Therapeutics, 2014, 13, 1826-1836.	4.1	59
215	Abstract 3154: RSK2-mediated phosphorylation of stathmin promotes microtubule polymerization, providing a pro-invasive advantage to metastatic cancer cells. , 2014, , .		1
216	Abstract 349: mTOR complex 2 (mTORC2) positively regulates Mcl-1 stability by suppressing GSK3-dependent and FBXW7-mediated proteasomal degradation of Mcl-1. Cancer Research, 2014, 74, 349-349.	0.9	1

#	ARTICLE	IF	CITATIONS
217	Expressions of EGFR, HER2, and HER3 and their correlations with clinical characteristics in oropharyngeal squamous cell carcinoma (OPSCC).. Journal of Clinical Oncology, 2014, 32, 6068-6068.	1.6	1
218	Racial disparities in the incidence and survival trends in women with squamous cell carcinoma of the oral tongue based on the Surveillance, Epidemiology, and End Results (SEER) analysis.. Journal of Clinical Oncology, 2014, 32, 6085-6085.	1.6	1
219	Second primary lung cancers: Analysis of E5597 selenium chemoprevention study.. Journal of Clinical Oncology, 2014, 32, 7518-7518.	1.6	1
220	Clinical characteristics and outcomes of atypical carcinoid (AC) tumor of the lung: A Surveillance, Epidemiology, and End Results database analysis.. Journal of Clinical Oncology, 2014, 32, 7554-7554.	1.6	1
221	Pro-oncogenic function of HIP-55/Drebrin-like (DBNL) through Ser269/Thr291-phospho-sensor motifs. Oncotarget, 2014, 5, 3197-3209.	1.8	13
222	Synthetic Curcumin Analog UBS109 Inhibits the Growth of Head and Neck Squamous Cell Carcinoma Xenografts. Current Cancer Drug Targets, 2014, 14, 380-393.	1.6	12
223	Phenformin combines with selumetinib in targeting KRAS mutant non-small cell lung cancer cells with alternative LKB1 status.. Journal of Clinical Oncology, 2014, 32, 2589-2589.	1.6	1
224	Management approaches and outcomes of lung cancer patients hospitalized for malignant pleural effusions.. Journal of Clinical Oncology, 2014, 32, 9646-9646.	1.6	0
225	Predictive value of gene expression signatures in premalignant lesions of the head and neck for response to chemoprevention with EGFR and COX-2 inhibitors.. Journal of Clinical Oncology, 2014, 32, e17053-e17053.	1.6	1
226	HER2 mutations in lung adenocarcinoma: A report from the Lung Cancer Mutation Consortium (LCMC).. Journal of Clinical Oncology, 2014, 32, 8060-8060.	1.6	1
227	Trends in small cell lung cancer (SCLC) survival: Predictors and impact of systemic therapy.. Journal of Clinical Oncology, 2014, 32, 7599-7599.	1.6	0
228	Standardizing measurement of tobacco use in cancer clinical trials.. Journal of Clinical Oncology, 2014, 32, e17658-e17658.	1.6	0
229	Predictors and outcomes of venous thromboembolism (VTE) in hospitalized lung cancer patients: A nationwide inpatient sample (NIS) database analysis.. Journal of Clinical Oncology, 2014, 32, e17632-e17632.	1.6	0
230	Abstract 773: Restoration of LKB1 defect in EK VX cells leads to resistance to microtubule targeting agents. , 2014, , .		0
231	Abstract 2288: Pharmacological inhibition of B-Raf/MEK/ERK signaling suppresses DR5 expression and impairs cancer cell response to DR5 activation-induced apoptosis. , 2014, , .		0
232	Abstract 2758: Development of small molecule Bax agonists for lung cancer treatment. , 2014, , .		0
233	Abstract 922: Evaluating markers of cisplatin sensitivity and survival in small cell lung cancer. , 2014, , .		0
234	Abstract 1227: Preserved histological and molecular phenotypes following serial in vivo propagation of patient-derived xenografts of small cell lung cancer. , 2014, , .		0



#	ARTICLE	IF	CITATIONS
235	Abstract C26: Ethnic, gender, and age disparities and outcome of phase I clinical trials of biologically targeted anticancer agents. , 2014, , .		1
236	Advances in the management of recurrent or metastatic squamous cell carcinoma of the head and neck. Head and Neck, 2013, 35, 443-453.	2.0	33
237	Laryngeal tumor volume as a predictor for thyroid cartilage penetration. Head and Neck, 2013, 35, 426-430.	2.0	11
238	Correlates of continued smoking versus cessation among survivors of smoking-related cancers. Psycho-Oncology, 2013, 22, 799-806.	2.3	74
239	A Time-Resolved Fluorescence Resonance Energy Transfer Assay for High-Throughput Screening of 14-3-3 Protein-Protein Interaction Inhibitors. Assay and Drug Development Technologies, 2013, 11, 367-381.	1.2	27
240	Risk Factors for Rising Incidence of Esophageal and Gastric Cardia Adenocarcinoma. Journal of Gastrointestinal Cancer, 2013, 44, 143-151.	1.3	62
241	Soluble FAS ligand as a biomarker of disease recurrence in differentiated thyroid cancer. Cancer, 2013, 119, 1503-1511.	4.1	14
242	On collegiality and role models. Cancer, 2013, 119, 928-930.	4.1	1
243	Paranasal sinus squamous cell carcinoma incidence and survival based on Surveillance, Epidemiology, and End Results data, 1973 to 2009. Cancer, 2013, 119, 2602-2610.	4.1	166
244	Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. Lancet Oncology, The, 2013, 14, 257-264.	10.7	617
245	Novel Small-Molecule Inhibitors of Bcl-XL to Treat Lung Cancer. Cancer Research, 2013, 73, 5485-5496.	0.9	62
246	The E3 ubiquitin ligases $\beta$ -TrCP and FBXW7 cooperatively mediates GSK3-dependent Mcl-1 degradation induced by the Akt inhibitor API-1, resulting in apoptosis. Molecular Cancer, 2013, 12, 146.	19.2	58
247	Chemoprevention of Head and Neck Cancer by Simultaneous Blocking of Epidermal Growth Factor Receptor and Cyclooxygenase-2 Signaling Pathways: Preclinical and Clinical Studies. Clinical Cancer Research, 2013, 19, 1244-1256.	7.0	56
248	Tyr26 phosphorylation of PGAM1 provides a metabolic advantage to tumours by stabilizing the active conformation. Nature Communications, 2013, 4, 1790.	12.8	75
249	The PI3 kinase inhibitor NVP-BKM120 induces GSK3/FBXW7-dependent Mcl-1 degradation, contributing to induction of apoptosis and enhancement of TRAIL-induced apoptosis. Cancer Letters, 2013, 338, 229-238.	7.2	28
250	Targeting protein-protein interactions as an anticancer strategy. Trends in Pharmacological Sciences, 2013, 34, 393-400.	8.7	307
251	Survival Analysis of Patients With Stage I Non-Small-Cell Lung Cancer Using Clinical and DNA Repair Pathway Expression Variables. Clinical Lung Cancer, 2013, 14, 128-138.	2.6	3
252	CHFR Protein Expression Predicts Outcomes to Taxane-Based First Line Therapy in Metastatic NSCLC. Clinical Cancer Research, 2013, 19, 1603-1611.	7.0	21

#	ARTICLE	IF	CITATIONS
253	mTOR Complex 2 Is Involved in Regulation of Cbl-Dependent c-FLIP Degradation and Sensitivity of TRAIL-Induced Apoptosis. <i>Cancer Research</i> , 2013, 73, 1946-1957.	0.9	36
254	Clinical Efficacy of Targeted Biologic Agents as Second-Line Therapy of Advanced Thyroid Cancer. <i>Oncologist</i> , 2013, 18, 1262-1269.	3.7	13
255	p90 RSK2 Mediates Antiankist Signals by both Transcription-Dependent and -Independent Mechanisms. <i>Molecular and Cellular Biology</i> , 2013, 33, 2574-2585.	2.3	28
256	Integration of Apoptosis Signal-Regulating Kinase 1-Mediated Stress Signaling with the Akt/Protein Kinase B-I $\kappa$ B Kinase Cascade. <i>Molecular and Cellular Biology</i> , 2013, 33, 2252-2259.	2.3	28
257	Protein Phosphatase 2A and DNA-dependent Protein Kinase Are Involved in Mediating Rapamycin-induced Akt Phosphorylation. <i>Journal of Biological Chemistry</i> , 2013, 288, 13215-13224.	3.4	47
258	Niclosamide Overcomes Acquired Resistance to Erlotinib through Suppression of STAT3 in Non-Small Cell Lung Cancer. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 2200-2212.	4.1	137
259	The Prometastatic Ribosomal S6 Kinase 2-cAMP Response Element-binding Protein (RSK2-CREB) Signaling Pathway Up-regulates the Actin-binding Protein Fascin-1 to Promote Tumor Metastasis. <i>Journal of Biological Chemistry</i> , 2013, 288, 32528-32538.	3.4	45
260	Gefitinib Versus Placebo in Completely Resected Non-Small-Cell Lung Cancer: Results of the NCIC CTG BR19 Study. <i>Journal of Clinical Oncology</i> , 2013, 31, 3320-3326.	1.6	327
261	Real-World Effectiveness of Systemic Agents Approved for Advanced Non-Small Cell Lung Cancer: A SEER-Medicare Analysis. <i>Oncologist</i> , 2013, 18, 600-610.	3.7	33
262	Randomized, Double-Blind, Placebo-Controlled, Phase III Chemoprevention Trial of Selenium Supplementation in Patients With Resected Stage I Non-Small-Cell Lung Cancer: ECOG 5597. <i>Journal of Clinical Oncology</i> , 2013, 31, 4179-4187.	1.6	96
263	Follow-up to expression of concern. <i>Cancer</i> , 2013, 119, 1763-1763.	4.1	0
264	Energizing the Search to Target LKB1-Mutant Tumors. <i>Cancer Discovery</i> , 2013, 3, 843-845.	9.4	2
265	Prognostic impact of Fas-associated death domain, a key component in death receptor signaling, is dependent on the presence of lymph node metastasis in head and neck squamous cell carcinoma. <i>Cancer Biology and Therapy</i> , 2013, 14, 365-369.	3.4	19
266	A phase 1 Bayesian dose selection study of bortezomib and sunitinib in patients with refractory solid tumor malignancies. <i>British Journal of Cancer</i> , 2013, 108, 762-765.	6.4	22
267	Phase II Study of Docetaxel in Combination with Everolimus for Second- or Third-Line Therapy of Advanced Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2013, 8, 369-372.	1.1	37
268	Abstract 1460: Quantification of circulating tumor cells using multiplexed Surface-Enhanced Raman Scattering Nanoparticles.., 2013,, .		2
269	Abstract B30: Class I HDACs are mediators of smoke-carcinogen induced stabilization of DNMT1 and serve as promising targets for chemoprevention of lung cancer. <i>Cancer Research</i> , 2013, 73, B30-B30.	0.9	1
270	Targeting the PI3K/AKT/mTOR Pathway: Biomarkers of Success and Tribulation. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, 33, e395-e401.	3.8	67



#	ARTICLE	IF	CITATIONS
271	A randomized study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel versus docetaxel alone for second-line therapy of lung adenocarcinoma (GALAXY-1).. Journal of Clinical Oncology, 2013, 31, CRA8007-CRA8007.	1.6	12
272	Inhibition of STAT3 by Niclosamide Synergizes with Erlotinib against Head and Neck Cancer. PLoS ONE, 2013, 8, e74670.	2.5	73
273	Targeting the PI3K/AKT/mTOR Pathway: Biomarkers of Success and Tribulation. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , e395-e401.	3.8	51
274	Interactive Software for Isotonic Design using Normalized Equivalent Toxicity Score (ID-NETS <sup>®</sup> ) for Cancer Phase I Clinical Trials. Open Medical Informatics Journal, 2013, 7, 8-17.	1.0	3
275	Abstract 3282: Poly (ADP) ribose polymerase (PARP) enzyme inhibitor, CEP8983, potentiates bendamustine activity in small cell lung cancer (SCLC).. , 2013, , .		0
276	Abstract 3449: Development of small molecule Bcl-XL inhibitors for treatment of lung cancer.. , 2013, , .		0
277	Abstract 2925: p90RSK2 coordinates pro-apoptotic and anti-apoptotic signaling pathways to protect cancer cells from anoikis.. , 2013, , .		0
278	Abstract LB-194: Window of opportunity preoperative interrogation of mTOR pathway in patients with resectable non-small cell lung cancer (NSCLC).. , 2013, , .		0
279	Screening of novel small molecule inhibitors of NF- $\kappa$ B activation in lung cancer. FASEB Journal, 2013, 27, lb581.	0.5	0
280	Abstract 3189: Potent curcumin analogue FLLL-12 targets protein translational pathways to inhibit EGFR, AKT and Bcl-2: potential role in apoptosis induction.. , 2013, , .		0
281	Abstract 2625: Knockdown of death receptor 5 promotes cancer cell invasion through activation of the ERK and JNK signaling pathways.. , 2013, , .		0
282	Abstract LB-41: Rictor undergoes GSK3-dependent, FBXW7-mediated ubiquitination and proteasomal degradation.. , 2013, , .		0
283	Abstract 1975: AICAR induces cell death in LKB1-deficient NSCLC.. , 2013, , .		0
284	Abstract LB-79: Combined treatment with HER3 antibody MM-121/SAR 256212 and EGFR antibody cetuximab in pre-clinical models of head and neck cancer.. , 2013, , .		0
285	Rapamycin Induces Bad Phosphorylation in Association with Its Resistance to Human Lung Cancer Cells. Molecular Cancer Therapeutics, 2012, 11, 45-56.	4.1	40
286	Elevated expression of eukaryotic translation initiation factor 4E is associated with proliferation, invasion and acquired resistance to erlotinib in lung cancer. Cancer Biology and Therapy, 2012, 13, 272-280.	3.4	52
287	Genetic Variants in the PI3K/PTEN/AKT/mTOR Pathway Predict Head and Neck Cancer Patient Second Primary Tumor/Recurrence Risk and Response to Retinoid Chemoprevention. Clinical Cancer Research, 2012, 18, 3705-3713.	7.0	49
288	Oncogenic Ras and B-Raf Proteins Positively Regulate Death Receptor 5 Expression through Co-activation of ERK and JNK Signaling. Journal of Biological Chemistry, 2012, 287, 257-267.	3.4	35

#	ARTICLE	IF	CITATIONS
289	A Systematic Analysis of Efficacy of Second-Line Chemotherapy in Sensitive and Refractory Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2012, 7, 866-872.	1.1	117
290	The Novel Akt Inhibitor API-1 Induces c-FLIP Degradation and Synergizes with TRAIL to Augment Apoptosis Independent of Akt Inhibition. <i>Cancer Prevention Research</i> , 2012, 5, 612-620.	1.5	15
291	Phosphoglycerate Mutase 1 Coordinates Glycolysis and Biosynthesis to Promote Tumor Growth. <i>Cancer Cell</i> , 2012, 22, 585-600.	16.8	329
292	1187 Molecular Mechanism of Synergistic Anti-tumor Activity by the Combination of Natural Compounds Green Tea (-)Epigallocatechin-3-gallate (EGCG) and Resveratrol for Potential Chemoprevention in Head and Neck Cancer (HNC). <i>European Journal of Cancer</i> , 2012, 48, S286.	2.8	4
293	Synthetic curcumin analog EF31 inhibits the growth of head and neck squamous cell carcinoma xenografts. <i>Integrative Biology (United Kingdom)</i> , 2012, 4, 633-640.	1.3	32
294	NNK promotes migration and invasion of lung cancer cells through activation of c-Src/PKC $\beta$ /FAK loop. <i>Cancer Letters</i> , 2012, 318, 106-113.	7.2	53
295	Single agent maintenance therapy for advanced stage non-small cell lung cancer: A meta-analysis. <i>Lung Cancer</i> , 2012, 77, 331-338.	2.0	51
296	The combination of RAD001 and NVP-BKM120 synergistically inhibits the growth of lung cancer in vitro and in vivo. <i>Cancer Letters</i> , 2012, 325, 139-146.	7.2	54
297	HPV Positive Squamous Cell Carcinoma of the Oropharynx. Are we Observing an Unusual Pattern of Metastases?. <i>Head and Neck Pathology</i> , 2012, 6, 336-344.	2.6	64
298	c-Myc Suppression of DNA Double-strand Break Repair. <i>Neoplasia</i> , 2012, 14, 1190-IN35.	5.3	48
299	Therapeutic misconception, misestimation, and optimism in participants enrolled in phase 1 trials. <i>Cancer</i> , 2012, 118, 4571-4578.	4.1	119
300	Lung cancer with translocation in the anaplastic lymphoma kinase gene. <i>Cancer</i> , 2012, 118, 4370-4371.	4.1	0
301	Adenoid cystic carcinoma of the head and neck. <i>Cancer</i> , 2012, 118, 4444-4451.	4.1	251
302	Human immunodeficiency virus-associated lung cancer in the era of highly active antiretroviral therapy. <i>Cancer</i> , 2012, 118, 164-172.	4.1	35
303	Expression of concern. <i>Cancer</i> , 2012, 118, 1173-1173.	4.1	0
304	A phase I study of the safety and pharmacodynamic effects of everolimus in combination with lenalidomide in patients with advanced solid malignancies.. <i>Journal of Clinical Oncology</i> , 2012, 30, 2576-2576.	1.6	2
305	The PARADIGM trial: A phase III study comparing sequential therapy (ST) to concurrent chemoradiotherapy (CRT) in locally advanced head and neck cancer (LANHC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 5501-5501.	1.6	30
306	Abstract 112: An endogenous mTOR inhibitor, PRAS40, is upregulated in lung cancer and contributes to tumor cell invasion and chemoresistance. , 2012, , .		1

#	ARTICLE	IF	CITATIONS
307	Abstract 4498: Prognostic significance of nuclear factor kappa B expression in human papillomavirus-associated oropharyngeal cancer. , 2012, , .		0
308	Abstract 2803: GSK3 plays a crucial role in determining cell response to mTOR inhibitors. , 2012, , .		0
309	Abstract 1588: Synergistic apoptosis by combination of natural compound EGCG and resveratrol in head and neck cancer: Potential role for AKT-dependent signaling. , 2012, , .		0
310	Abstract 261: The novel Akt inhibitor API-1 induces c-FLIP degradation and synergizes with TRAIL to augment apoptosis independent of Akt inhibition. , 2012, , .		0
311	Abstract 2207: SUMOylation of EAPII/TTRAP/TDP2 modulates its function. , 2012, , .		0
312	Abstract 4885: mTOR complex 2 is involved in regulation of c-FLIP stability and sensitization of TRAIL-induced apoptosis. , 2012, , .		0
313	Abstract 2955: c-Myc suppresses DNA double-strand break repair. , 2012, , .		0
314	Retinoic Acid Enhances TRAIL-Induced Apoptosis in Cancer Cells by Upregulating TRAIL Receptor 1 Expression. Cancer Research, 2011, 71, 5245-5254.	0.9	41
315	The BATTLE Trial: Personalizing Therapy for Lung Cancer. Cancer Discovery, 2011, 1, 44-53.	9.4	778
316	Detection of Circulating Tumor Cells in Human Peripheral Blood Using Surface-Enhanced Raman Scattering Nanoparticles. Cancer Research, 2011, 71, 1526-1532.	0.9	327
317	Tyrosine Phosphorylation of Mitochondrial Pyruvate Dehydrogenase Kinase 1 Is Important for Cancer Metabolism. Molecular Cell, 2011, 44, 864-877.	9.7	278
318	14-3-3 proteins as potential therapeutic targets. Seminars in Cell and Developmental Biology, 2011, 22, 705-712.	5.0	140
319	1230 POSTER A Phase 1 and Pharmacokinetic Study of Ganetespib (STA-9090), a Heat Shock Protein 90 Inhibitor, in Combination With Docetaxel in Subjects With Advanced Solid Tumour Malignancies. European Journal of Cancer, 2011, 47, S153.	2.8	2
320	The Combination of RAD001 and NVP-BEZ235 Exerts Synergistic Anticancer Activity against Non-Small Cell Lung Cancer In Vitro and In Vivo. PLoS ONE, 2011, 6, e20899.	2.5	64
321	Global Assessment of Genetic Variation Influencing Response to Retinoid Chemoprevention in Head and Neck Cancer Patients. Cancer Prevention Research, 2011, 4, 185-193.	1.5	36
322	Oncogenic role of EAPII in lung cancer development and its activation of the MAPK/ERK pathway. Oncogene, 2011, 30, 3802-3812.	5.9	35
323	Lung cancer: New biological insights and recent therapeutic advances. Ca-A Cancer Journal for Clinicians, 2011, 61, 91-112.	329.8	413
324	The NEDD8-Activating Enzyme Inhibitor, MLN4924, Cooperates with TRAIL to Augment Apoptosis through Facilitating c-FLIP Degradation in Head and Neck Cancer Cells. Molecular Cancer Therapeutics, 2011, 10, 2415-2425.	4.1	40

#	ARTICLE	IF	CITATIONS
325	Celecoxib Promotes c-FLIP Degradation through Akt-Independent Inhibition of GSK3. Cancer Research, 2011, 71, 6270-6281.	0.9	35
326	Statistical learning methods as a preprocessing step for survival analysis: evaluation of concept using lung cancer data. BioMedical Engineering OnLine, 2011, 10, 97.	2.7	13
327	Farnesyl transferase expression determines clinical response to the docetaxel+onafarnib combination in patients with advanced malignancies. Cancer, 2011, 117, 4049-4059.	4.1	16
328	Patterns of extralaryngeal spread of laryngeal cancer. Cancer, 2011, 117, 5047-5051.	4.1	28
329	Why <i>Cancer</i> matters. Cancer, 2011, 117, 5436-5438.	4.1	1
330	Pleiotropic functions of EAPII/TTRAP/TDP2. Cell Cycle, 2011, 10, 3274-3283.	2.6	25
331	Gender and Ethnic Disparities in Incidence and Survival of Squamous Cell Carcinoma of the Oral Tongue, Base of Tongue, and Tonsils: A Surveillance, Epidemiology and End Results Program-Based Analysis. Oncology, 2011, 81, 12-20.	1.9	96
332	The Dawn of a Revolution in Personalized Lung Cancer Prevention. Cancer Prevention Research, 2011, 4, 949-953.	1.5	5
333	Tyrosine Phosphorylation of Lactate Dehydrogenase A Is Important for NADH/NAD <sup>+</sup> Redox Homeostasis in Cancer Cells. Molecular and Cellular Biology, 2011, 31, 4938-4950.	2.3	193
334	Discovery and structural characterization of a small molecule 14-3-3 protein-protein interaction inhibitor. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 16212-16216.	7.1	93
335	Augmentation of NVP-BEZ235's anticancer activity against human lung cancer cells by blockage of autophagy. Cancer Biology and Therapy, 2011, 12, 549-555.	3.4	56
336	Abstract 5525: Profiling counter-regulatory and cytotoxic immune pathways with cellular biomarkers in thyroid cancer patients. , 2011, , .		1
337	A randomized phase II/III trial of a tumor vascular disrupting agent fosbretabulin tromethamine (CA4P) with carboplatin (C) and paclitaxel (P) in anaplastic thyroid cancer (ATC): Final survival analysis for the FACT trial.. Journal of Clinical Oncology, 2011, 29, 5502-5502.	1.6	24
338	Single-agent maintenance therapy for advanced-stage non-small cell lung cancer: A meta-analysis.. Journal of Clinical Oncology, 2011, 29, 7553-7553.	1.6	3
339	Everolimus, an mTOR inhibitor, in combination with docetaxel for second- or third-line therapy of advanced-stage non-small cell lung cancer: A phase II study.. Journal of Clinical Oncology, 2011, 29, e13601-e13601.	1.6	2
340	Diagnosis and Multidisciplinary Treatment of Laryngeal Cancers. , 2011, , 471-481.		0
341	Abstract 2116: The Cables1 protein complex couples survival signaling to cell death machinery. , 2011, , .		0
342	Abstract 1058: LKB1 negatively regulates IGF-1 induced ERK phosphorylation. , 2011, , .		0

#	ARTICLE	IF	CITATIONS
343	Abstract 841: Inhibition of head and neck squamous cell carcinoma growth by combination treatment of erlotinib and celecoxib: Potential chemopreventive agents. , 2011, , .		0
344	Abstract 2798: Tyrosine phosphorylation of LDH-A is important for cancer cell redox homeostasis and tumor growth. , 2011, , .		0
345	Abstract 2567: Preclinical evaluation of Poly (ADP) Ribose Polymerase (PARP) enzyme inhibitor, ABT-888, in combination with cytotoxic agents in small cell lung cancer (SCLC). , 2011, , .		0
346	Abstract 1953: Elevated eukaryotic translation initiation factor 4E (eIF4E) is involved in erlotinib resistance. , 2011, , .		0
347	Abstract 1257: Tyrosine phosphorylation of mitochondrial pyruvate dehydrogenase kinase 1 is important for cancer metabolism. , 2011, , .		0
348	Abstract 1132: Oncogenic role of EAPII/TTRAP in lung cancer development and its activation of MAPK-ERK pathway. , 2011, , .		0
349	Abstract 4782: The NEDD8-activating enzyme inhibitor, MLN4924, cooperates with TRAIL to augment apoptosis through JNK-dependent downregulation of c-FLIP in head and neck cancer cells. , 2011, , .		0
350	Abstract 1011: NNK promotes migration and invasion of cancer cells through activation of c-Src, PKC $\beta$ 1 and FAK loop. , 2011, , .		0
351	Abstract 2342: RSK2 phosphorylates and activates CREB to promote HNSCC cell invasion through upregulation of pro-metastatic MCAM and Fascin-1. , 2011, , .		0
352	Systematic comparative analysis of efficacy of EGFR tyrosine kinase inhibitors (TKIs) in the frontline versus salvage therapy of NSCLC.. Journal of Clinical Oncology, 2011, 29, 7602-7602.	1.6	0
353	Adenoid cystic carcinoma of the head and neck (ACCHN) incidence and survival trends.. Journal of Clinical Oncology, 2011, 29, 5580-5580.	1.6	1
354	Salvage tyrosine kinase inhibitor therapy for differentiated and medullary thyroid cancer.. Journal of Clinical Oncology, 2011, 29, e16036-e16036.	1.6	0
355	Survival outcomes of nonoperative therapy (NOT) alone versus NOT followed by surgery (NOTS) in patients with esophageal cancer (EC): SEER analysis 2000-2007.. Journal of Clinical Oncology, 2011, 29, e14569-e14569.	1.6	0
356	Comparison of native and adaptive immunity profiles of healthy volunteers and patients with well-differentiated thyroid cancer.. Journal of Clinical Oncology, 2011, 29, 5585-5585.	1.6	1
357	Abstract A41: The ASK1/IKK signaling axis mediates crosstalk between inflammation and apoptosis. , 2011, , .		0
358	PLENARY. Journal of Thoracic Oncology, 2010, 5, S501-S503.	1.1	1
359	Comparison and optimization of multiplexed quantum dot-based immunohistofluorescence. Nano Research, 2010, 3, 61-68.	10.4	22
360	Cancer Prevention With Natural Compounds. Seminars in Oncology, 2010, 37, 258-281.	2.2	425

#	ARTICLE	IF	CITATIONS
361	Activation of the p38 pathway by a novel monoketone curcumin analog, EF24, suggests a potential combination strategy. <i>Biochemical Pharmacology</i> , 2010, 80, 1309-1316.	4.4	48
362	Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer. <i>Cancer</i> , 2010, 116, 3903-3909.	4.1	36
363	Dual engagement of 14-3-3 proteins controls signal relay from ASK2 to the ASK1 signalosome. <i>Oncogene</i> , 2010, 29, 822-830.	5.9	35
364	Mono- or Double-Site Phosphorylation Distinctly Regulates the Proapoptotic Function of Bax. <i>PLoS ONE</i> , 2010, 5, e13393.	2.5	28
365	Prevention of Lung Cancer: Future Perspective with Natural Compounds. <i>Tuberculosis and Respiratory Diseases</i> , 2010, 69, 1.	1.8	6
366	Enhanced Anti-tumor Activity by the Combination of the Natural Compounds (âˆ’)-Epigallocatechin-3-gallate and Luteolin. <i>Journal of Biological Chemistry</i> , 2010, 285, 34557-34565.	3.4	97
367	What is the role of maintenance therapy in the treatment of non-small cell lung cancer?. <i>Therapeutic Advances in Medical Oncology</i> , 2010, 2, 229-235.	3.2	3
368	MicroRNA-related genetic variations as predictors for risk of second primary tumor and/or recurrence in patients with early-stage head and neck cancer. <i>Carcinogenesis</i> , 2010, 31, 2118-2123.	2.8	52
369	Genetic variations in regulator of G-protein signaling genes as susceptibility loci for second primary tumor/recurrence in head and neck squamous cell carcinoma. <i>Carcinogenesis</i> , 2010, 31, 1755-1761.	2.8	20
370	Proteasome Inhibitor PS-341 (Bortezomib) Induces Calpain-dependent Î²BÎ± Degradation. <i>Journal of Biological Chemistry</i> , 2010, 285, 16096-16104.	3.4	91
371	ERK/Ribosomal S6 Kinase (RSK) Signaling Positively Regulates Death Receptor 5 Expression through Co-activation of CHOP and Elk1. <i>Journal of Biological Chemistry</i> , 2010, 285, 41310-41319.	3.4	56
372	The eIF4E/eIF4G Interaction Inhibitor 4EGI-1 Augments TRAIL-Mediated Apoptosis through c-FLIP Down-regulation and DR5 Induction Independent of Inhibition of Cap-Dependent Protein Translation. <i>Neoplasia</i> , 2010, 12, 346-IN7.	5.3	81
373	Dissecting the roles of DR4, DR5 and c-FLIP in the regulation of Geranylgeranyltransferase I inhibition-mediated augmentation of TRAIL-induced apoptosis. <i>Molecular Cancer</i> , 2010, 9, 23.	19.2	25
374	c-Jun NH2-terminal kinase-dependent upregulation of DR5 mediates cooperative induction of apoptosis by perifosine and TRAIL. <i>Molecular Cancer</i> , 2010, 9, 315.	19.2	29
375	Protein Phosphatase 2A Negatively Regulates Eukaryotic Initiation Factor 4E Phosphorylation and eIF4F Assembly through Direct Dephosphorylation of Mnk and eIF4E. <i>Neoplasia</i> , 2010, 12, 848-855.	5.3	69
376	p90 ribosomal S6 kinase 2 promotes invasion and metastasis of human head and neck squamous cell carcinoma cells. <i>Journal of Clinical Investigation</i> , 2010, 120, 1165-1177.	8.2	133
377	Chemoprevention with erlotinib and celecoxib in advanced premalignant lesions of the head and neck: Results of a phase I study.. <i>Journal of Clinical Oncology</i> , 2010, 28, 5535-5535.	1.6	2
378	PF-00299804 (PF299) patient (pt)-reported outcomes (PROs) and efficacy in adenocarcinoma (adeno) and nonadeno non-small cell lung cancer (NSCLC): A phase (P) II trial in advanced NSCLC after failure of chemotherapy (CT) and erlotinib (E).. <i>Journal of Clinical Oncology</i> , 2010, 28, 7596-7596.	1.6	33



#	ARTICLE	IF	CITATIONS
379	Survival impact of newly approved therapeutic agents in patients with advanced non-small cell lung cancer (NSCLC): A SEER-Medicare database analysis.. Journal of Clinical Oncology, 2010, 28, 7633-7633.	1.6	2
380	c-FLIP Degradation Mediates Sensitization of Pancreatic Cancer Cells to TRAIL-Induced Apoptosis by the Histone Deacetylase Inhibitor LBH589. PLoS ONE, 2010, 5, e10376.	2.5	46
381	Analysis of Death Receptor 5 and Caspase-8 Expression in Primary and Metastatic Head and Neck Squamous Cell Carcinoma and Their Prognostic Impact. PLoS ONE, 2010, 5, e12178.	2.5	41
382	Abstract 34: Oncogenic tyrosine kinases phosphorylate and inhibit PKM2 to provide a metabolic advantage to tumor growth. , 2010, , .		0
383	Abstract 203: The histone deacetylase inhibitor LBH589 sensitizes pancreatic cancer cells to TRAIL-induced apoptosis through induction of c-FLIP degradation. , 2010, , .		2
384	Abstract 1201: Inhibition of ASK1 through phosphorylation of serine 967 by PI3K/Akt-mediated pathways. , 2010, , .		0
385	Abstract 4119: Cytoplasmic location of CXCR4 is correlated to loss of EMT marker and activation of downstream signaling pathway in non-small cell lung cancer. , 2010, , .		1
386	Abstract 1260: Analysis of death receptor 5 and caspase-8 expression in primary and metastatic head and neck squamous cell carcinoma and their prognostic impact. , 2010, , .		0
387	Abstract 2367: RSK2 promotes head and neck cancer cell invasion through direct phosphorylation of Hsp27 to regulate actin filaments. , 2010, , .		0
388	Abstract 3304: EAPII/TTRAP is overexpressed in HNSCC. , 2010, , .		0
389	Abstract 5428: Histone deacetylase (HDAC) enzyme inhibition potentiates taxanes and doxorubicin activity in thyroid cancer cell lines. , 2010, , .		0
390	Abstract LB-335: Retinoic acid regulates TRAIL-R1 expression through a retinoic acid receptor-dependent mechanism and enhances death receptor-induced apoptosis. , 2010, , .		0
391	Abstract 3744: Acetylated tubulin (AT) levels predicts response to TPF chemotherapy in locally advanced head and neck squamous cell carcinoma (HNSCC). , 2010, , .		0
392	Abstract 5649: Highly synergistic anti-tumor efficacy induced by the combination of two natural dietary agents, luteolin and EGCG: Role of p53 phosphorylation, stabilization and translocation. , 2010, , .		1
393	Abstract 2910: Mono- or double-site phosphorylation distinctly regulates the proapoptotic function of Bax. , 2010, , .		0
394	Phase II Study of Vinorelbine and Docetaxel in the Treatment of Advanced Nonâ€“Small-Cell Lung Cancer as Frontline and Second-Line Therapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2010, 33, 148-152.	1.3	10
395	HIV-associated lung cancer in the era of highly active antiretroviral therapy (HAART): Correlation between CD4 count and outcome.. Journal of Clinical Oncology, 2010, 28, 7632-7632.	1.6	1
396	Phase IB dose escalation study of bortezomib and sunitinib in patients with refractory solid tumors.. Journal of Clinical Oncology, 2010, 28, 2538-2538.	1.6	5

#	ARTICLE	IF	CITATIONS
397	caGrid-Enabled caBIGTM Silver Level Compatible Head and Neck Cancer Tissue Database System. Open Medical Informatics Journal, 2010, 4, 171-178.	1.0	1
398	Leukemogenic Tyrosine Kinases Inhibit PKM2 to Promote the Warburg Effect and Tumor Growth. Blood, 2010, 116, 3142-3142.	1.4	0
399	Role of Cyclooxygenase-2 in Tumor Progression and Survival of Head and Neck Squamous Cell Carcinoma. Cancer Prevention Research, 2009, 2, 823-829.	1.5	49
400	The Protein Farnesyltransferase Regulates HDAC6 Activity in a Microtubule-dependent Manner. Journal of Biological Chemistry, 2009, 284, 9648-9655.	3.4	36
401	The Glycolytic Inhibitor 2-Deoxyglucose Activates Multiple Prosurvival Pathways through IGF1R. Journal of Biological Chemistry, 2009, 284, 23225-23233.	3.4	103
402	Durable Long-Term Remission With Chemotherapy Alone for Stage II to IV Laryngeal Cancer. Journal of Clinical Oncology, 2009, 27, 1976-1982.	1.6	47
403	Phosphorylated eukaryotic translation initiation factor 4 (eIF4E) is elevated in human cancer tissues. Cancer Biology and Therapy, 2009, 8, 1463-1469.	3.4	97
404	Randomized Trial of 13- <i>cis</i> Retinoic Acid Compared With Retinyl Palmitate With or Without Beta-Carotene in Oral Premalignancy. Journal of Clinical Oncology, 2009, 27, 599-604.	1.6	96
405	The Role of the Taxanes in the Treatment of Older Patients with Advanced Stage Non-small Cell Lung Cancer. Oncologist, 2009, 14, 412-424.	3.7	14
406	Celecoxib antagonizes perifosine's anticancer activity involving a cyclooxygenase-2-dependent mechanism. Molecular Cancer Therapeutics, 2009, 8, 2575-2585.	4.1	14
407	Synergistic Growth Inhibition of Squamous Cell Carcinoma of the Head and Neck by Erlotinib and Epigallocatechin-3-Gallate: The Role of p53-Dependent Inhibition of Nuclear Factor- $\kappa$ B. Cancer Prevention Research, 2009, 2, 538-545.	1.5	61
408	Perifosine Inhibits Mammalian Target of Rapamycin Signaling through Facilitating Degradation of Major Components in the mTOR Axis and Induces Autophagy. Cancer Research, 2009, 69, 8967-8976.	0.9	137
409	Novel Susceptibility Loci for Second Primary Tumors/Recurrence in Head and Neck Cancer Patients: Large-Scale Evaluation of Genetic Variants. Cancer Prevention Research, 2009, 2, 617-624.	1.5	55
410	Concurrent chemotherapy with intensity-modulated radiation therapy for locally advanced squamous cell carcinoma of the larynx and oropharynx: A retrospective single-institution analysis. Head and Neck, 2009, 31, 1447-1455.	2.0	14
411	Perspectives for Cancer Prevention With Natural Compounds. Journal of Clinical Oncology, 2009, 27, 2712-2725.	1.6	471
412	Quantum dot-based quantification revealed differences in subcellular localization of EGFR and E-cadherin between EGFR-TKI sensitive and insensitive cancer cells. Nanotechnology, 2009, 20, 225102.	2.6	24
413	Tyrosine Phosphorylation Inhibits PKM2 to Promote the Warburg Effect and Tumor Growth. Science Signaling, 2009, 2, ra73.	3.6	632
414	Distinct growth factor-induced dynamic mass redistribution (DMR) profiles for monitoring oncogenic signaling pathways in various cancer cells. Journal of Receptor and Signal Transduction Research, 2009, 29, 182-194.	2.5	17



#	ARTICLE	IF	CITATIONS
415	A Phase II Study of Lonafarnib (SCH66336) in Patients With Chemorefractory, Advanced Squamous Cell Carcinoma of the Head and Neck. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2009, 32, 274-279.	1.3	40
416	Optimizing systemic therapy in squamous cell carcinoma of the head and neck with a focus on targeted agents. <i>Current Opinion in Oncology</i> , 2009, 21, 232-237.	2.4	11
417	Phase I Trial of Weekly Topotecan and Gemcitabine in Patients With Solid Tumors. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2009, 32, 15-19.	1.3	4
418	Synergistic inhibition of head and neck tumor growth by green tea (âˆ“)â€“epigallocatechinâ€“gallate and EGFR tyrosine kinase inhibitor. <i>International Journal of Cancer</i> , 2008, 123, 1005-1014.	5.1	98
419	Inhibition of Î²B Kinase-Nuclear Factor-Î²B Signaling Pathway by 3,5-Bis(2-fluorobenzylidene)piperidin-4-one (EF24), a Novel Monoketone Analog of Curcumin. <i>Molecular Pharmacology</i> , 2008, 74, 654-661.	2.3	151
420	2-Deoxyglucose induces Akt phosphorylation via a mechanism independent of LKB1/AMP-activated protein kinase signaling activation or glycolysis inhibition. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 809-817.	4.1	79
421	Unraveling the Mystery of Erythropoietin-Stimulating Agents in Cancer Promotion. <i>Cancer Research</i> , 2008, 68, 4013-4017.	0.9	1
422	Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitorsâ€™ anticancer efficacy. <i>Cancer Biology and Therapy</i> , 2008, 7, 1952-1958.	3.4	86
423	Down-regulation of 14-3-3Î¶ suppresses anchorage-independent growth of lung cancer cells through anoikis activation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 162-167.	7.1	137
424	Coupling of Endoplasmic Reticulum Stress to CDDO-Meâ€“Induced Up-regulation of Death Receptor 5 via a CHOPâ€“Dependent Mechanism Involving JNK Activation. <i>Cancer Research</i> , 2008, 68, 7484-7492.	0.9	109
425	The natural product honokiol preferentially inhibits cellular FLICE-inhibitory protein and augments death receptorâ€“induced apoptosis. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 2212-2223.	4.1	47
426	LKB1 Is Necessary for Akt-Mediated Phosphorylation of Proapoptotic Proteins. <i>Cancer Research</i> , 2008, 68, 7270-7277.	0.9	68
427	Enhancing Mammalian Target of Rapamycin (mTOR)â€“Targeted Cancer Therapy by Preventing mTOR/Raptor Inhibition-Initiated, mTOR/Rictor-Independent Akt Activation. <i>Cancer Research</i> , 2008, 68, 7409-7418.	0.9	152
428	CAAT/Enhancer Binding Protein Homologous Proteinâ€“Dependent Death Receptor 5 Induction Is a Major Component of SHetA2-Induced Apoptosis in Lung Cancer Cells. <i>Cancer Research</i> , 2008, 68, 5335-5344.	0.9	44
429	The Tumor Suppressor LKB1 Regulates Lung Cancer Cell Polarity by Mediating cdc42 Recruitment and Activity. <i>Cancer Research</i> , 2008, 68, 740-748.	0.9	83
430	Insulin-like Growth Factor-I Receptor Signaling Pathway Induces Resistance to the Apoptotic Activities of SCH66336 (Lonafarnib) through Akt/Mammalian Target of Rapamycinâ€“Mediated Increases in Survivin Expression. <i>Clinical Cancer Research</i> , 2008, 14, 1581-1589.	7.0	51
431	Head and Neck Cancer Chemoprevention Gets a Shot in the Arm. <i>Journal of Clinical Oncology</i> , 2008, 26, 345-347.	1.6	26
432	Involvement of c-FLIP and survivin down-regulation in flexible heteroarotinoid-induced apoptosis and enhancement of TRAIL-initiated apoptosis in lung cancer cells. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 3556-3565.	4.1	48

#	ARTICLE	IF	CITATIONS
433	From Nihilism to Individualism. American Journal of Respiratory and Critical Care Medicine, 2008, 177, 1299-1300.	5.6	2
434	Phase III Trial Comparing Carboplatin, Paclitaxel, and Bexarotene With Carboplatin and Paclitaxel in Chemotherapy-Naïve Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer: SPIRIT II. Journal of Clinical Oncology, 2008, 26, 1879-1885.	1.6	93
435	Laryngeal squamous cell carcinoma metastatic to a flank intramuscular lipoma. American Surgeon, 2008, 74, 447-448.	0.8	1
436	Research participants' views of nontherapeutic biopsies. Journal of Clinical Oncology, 2008, 26, 13529-13529.	1.6	1
437	A Homogenous Luminescent Proximity Assay for 14-3-3 Interactions with Both Phosphorylated and Nonphosphorylated Client Peptides. Current Chemical Genomics, 2008, 2, 40-47.	2.0	14
438	Inhibition of Mammalian Target of Rapamycin Induces Phosphatidylinositol 3-Kinase-Dependent and Mnk-Mediated Eukaryotic Translation Initiation Factor 4E Phosphorylation. Molecular and Cellular Biology, 2007, 27, 7405-7413.	2.3	137
439	Can Statins Pass the Aspirin Litmus Test in Cancer?. Journal of Clinical Oncology, 2007, 25, 3395-3396.	1.6	2
440	Translation of Innovative Designs Into Phase I Trials. Journal of Clinical Oncology, 2007, 25, 4982-4986.	1.6	190
441	Assessment of apoptosis-inducing effects of docetaxel combined with the proteasome inhibitor PS-341 in human lung cancer cells. Cancer Biology and Therapy, 2007, 6, 749-754.	3.4	8
442	Erythropoietins in Oncology. New England Journal of Medicine, 2007, 357, 1262-1263.	27.0	0
443	Weighing the Hazards of Erythropoiesis Stimulation in Patients with Cancer. New England Journal of Medicine, 2007, 356, 2445-2448.	27.0	93
444	PPAR $\gamma$ ligands enhance TRAIL-induced apoptosis through DR5 upregulation and c-FLIP downregulation in human lung cancer cells. Cancer Biology and Therapy, 2007, 6, 99-106.	3.4	53
445	Lipid Rafts and Nonrafts Mediate Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptotic and Nonapoptotic Signals in Non-Small Cell Lung Carcinoma Cells. Cancer Research, 2007, 67, 6946-6955.	0.9	139
446	Proliferative Changes in the Bronchial Epithelium of Former Smokers Treated With Retinoids. Journal of the National Cancer Institute, 2007, 99, 1603-1612.	6.3	18
447	c-FLIP downregulation contributes to apoptosis induction by the novel synthetic triterpenoid methyl-2-cyano-3, 12-dioxooleana-1, 9-dien-28-oate (CDDO-Me) in human lung cancer cells. Cancer Biology and Therapy, 2007, 6, 1614-1620.	3.4	48
448	CCAAT/Enhancer Binding Protein Homologous Protein-Dependent Death Receptor 5 Induction and Ubiquitin/Proteasome-Mediated Cellular FLICE-Inhibitory Protein Down-Regulation Contribute to Enhancement of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis by Dimethyl-Celecoxib in Human Non-Small-Cell Lung Cancer Cells. Molecular Pharmacology, 2007, 72, 1269-1279.	2.3	45
449	The Farnesyltransferase Inhibitor R115777 Up-regulates the Expression of Death Receptor 5 and Enhances TRAIL-Induced Apoptosis in Human Lung Cancer Cells. Cancer Research, 2007, 67, 4973-4980.	0.9	14
450	Farnesyl transferase inhibitors impair chromosomal maintenance in cell lines and human tumors by compromising CENP-E and CENP-F function. Molecular Cancer Therapeutics, 2007, 6, 1317-1328.	4.1	71

#	ARTICLE	IF	CITATIONS
451	The Farnesyltransferase Inhibitor Lonafarnib Induces CCAAT/Enhancer-binding Protein Homologous Protein-dependent Expression of Death Receptor 5, Leading to Induction of Apoptosis in Human Cancer Cells. <i>Journal of Biological Chemistry</i> , 2007, 282, 18800-18809.	3.4	49
452	The alkylphospholipid perifosine induces apoptosis of human lung cancer cells requiring inhibition of Akt and activation of the extrinsic apoptotic pathway. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 2029-2038.	4.1	87
453	14-3-3 integrates prosurvival signals mediated by the AKT and MAPK pathways in ZNF198-FGFR1-transformed hematopoietic cells. <i>Blood</i> , 2007, 110, 360-369.	1.4	66
454	M08-04: Retinoids and rexinoids in lung cancer biology and therapy. <i>Journal of Thoracic Oncology</i> , 2007, 2, S174.	1.1	0
455	Chemoprevention of squamous cell carcinoma of the head and neck. <i>Current Opinion in Oncology</i> , 2007, 19, 180-187.	2.4	20
456	Targeting Angiogenesis in Head and Neck Cancer. <i>Current Cancer Drug Targets</i> , 2007, 7, 643-649.	1.6	9
457	The Proteasome Inhibitor PS-341 (Bortezomib) Up-Regulates DR5 Expression Leading to Induction of Apoptosis and Enhancement of TRAIL-Induced Apoptosis Despite Up-Regulation of c-FLIP and Survivin Expression in Human NSCLC Cells. <i>Cancer Research</i> , 2007, 67, 4981-4988.	0.9	150
458	Induction of cell cycle arrest and apoptosis by a combined treatment with 13-cis-retinoic acid, interferon- $\gamma$ , and $\alpha$ -tocopherol in squamous cell carcinoma of the head and neck. <i>Head and Neck</i> , 2007, 29, 351-361.	2.0	11
459	Moving Toward Bioadjuvant Approaches to Head and Neck Cancer Prevention. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, S132-S135.	0.8	4
460	Concurrent platinum-based chemotherapy with intensity modulated radiation therapy (IMRT) for locally advanced squamous cell carcinoma of the head and neck (SCCHN): A retrospective single institution analysis. <i>Journal of Clinical Oncology</i> , 2007, 25, 16511-16511.	1.6	0
461	Taxanes in the Treatment of Non-Small Cell Lung Cancer. <i>Treatments in Respiratory Medicine</i> , 2006, 5, 181-191.	1.4	6
462	Fibronectin Stimulates Non-Small Cell Lung Carcinoma Cell Growth through Activation of Akt/Mammalian Target of Rapamycin/S6 Kinase and Inactivation of LKB1/AMP-Activated Protein Kinase Signaling Pathways. <i>Cancer Research</i> , 2006, 66, 315-323.	0.9	190
463	Update in the management of head and neck cancer. <i>Update on Cancer Therapeutics</i> , 2006, 1, 211-219.	0.4	8
464	Targeting mTOR Signaling for Lung Cancer Therapy. <i>Journal of Thoracic Oncology</i> , 2006, 1, 109-111.	1.1	8
465	Chronic myelomonocytic leukaemia after platinum-based therapy for non-small cell lung cancer: case report and review of the literature. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2006, 31, 401-406.	1.5	14
466	Dynamic 14-3-3/client protein interactions integrate survival and apoptotic pathways. <i>Seminars in Cancer Biology</i> , 2006, 16, 193-202.	9.6	151
467	Depletion of intracellular Glutathione Contributes to JNK-Mediated Death Receptor 5 Upregulation and Apoptosis Induction by the Novel Synthetic Triterpenoid Methyl-2-cyano-3, 12-dioxooleana-1, 9-dien-28-oate (CDDO-Me). <i>Cancer Biology and Therapy</i> , 2006, 5, 492-497.	3.4	54
468	Randomized Phase III Trial of Low-dose Isotretinoin for Prevention of Second Primary Tumors in Stage I and II Head and Neck Cancer Patients. <i>Journal of the National Cancer Institute</i> , 2006, 98, 441-450.	6.3	226

#	ARTICLE	IF	CITATIONS
469	The future of cancer prevention: ripe for a revolution. <i>Future Oncology</i> , 2006, 2, 159-160.	2.4	0
470	Phase I/II Study of Docetaxel, Cisplatin, and Concomitant Boost Radiation for Locally Advanced Squamous Cell Cancer of the Head and Neck. <i>Journal of Clinical Oncology</i> , 2006, 24, 4163-4169.	1.6	59
471	Fenretinide Activity in Retinoid-Resistant Oral Leukoplakia. <i>Clinical Cancer Research</i> , 2006, 12, 3109-3114.	7.0	48
472	Vitamin C Inactivates the Proteasome Inhibitor PS-341 in Human Cancer Cells. <i>Clinical Cancer Research</i> , 2006, 12, 273-280.	7.0	96
473	Monitoring 14-3-3 Protein Interactions with a Homogeneous Fluorescence Polarization Assay. <i>Journal of Biomolecular Screening</i> , 2006, 11, 269-276.	2.6	35
474	Cellular FLICE-Inhibitory Protein Down-regulation Contributes to Celecoxib-Induced Apoptosis in Human Lung Cancer Cells. <i>Cancer Research</i> , 2006, 66, 11115-11119.	0.9	69
475	Identification of Insulin-Like Growth Factor Binding Protein-3 as a Farnesyl Transferase Inhibitor SCH66336-Induced Negative Regulator of Angiogenesis in Head and Neck Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2006, 12, 653-661.	7.0	48
476	Farnesyltransferase Inhibitors Reverse Taxane Resistance. <i>Cancer Research</i> , 2006, 66, 8838-8846.	0.9	32
477	Targeting mTOR Signaling for Lung Cancer Therapy. <i>Journal of Thoracic Oncology</i> , 2006, 1, 109-111.	1.1	17
478	Antitumor effects of combined bortezomib and tipifarnib in head and neck squamous cell carcinoma (HNSCC) cells. <i>Journal of Clinical Oncology</i> , 2006, 24, 5581-5581.	1.6	4
479	Targeting the epidermal growth factor receptor. <i>Trials in head and neck and lung cancer. Oncology</i> , 2006, 20, 153-61; discussion 162, 166, 169 passim.	0.5	13
480	Targeting mTOR signaling for lung cancer therapy. <i>Journal of Thoracic Oncology</i> , 2006, 1, 109-11.	1.1	9
481	Phase 2 Bioadjuvant Study of Interferon Alfa-2a, Isotretinoin, and Vitamin E in Locally Advanced Squamous Cell Carcinoma of the Head and Neck. <i>JAMA Otolaryngology</i> , 2005, 131, 304.	1.2	41
482	The combination of the farnesyl transferase inhibitor lonafarnib and the proteasome inhibitor bortezomib induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKT. <i>Blood</i> , 2005, 106, 4322-4329.	1.4	56
483	A phase I/II study of neoadjuvant chemotherapy followed by radiation with boost chemotherapy for advanced T-stage nasopharyngeal carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 63, 717-724.	0.8	23
484	Chemoprevention Strategies for Patients with Lung Cancer in the Context of Screening. <i>Clinical Lung Cancer</i> , 2005, 7, 92-99.	2.6	10
485	Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant nonsmall cell lung carcinoma. <i>Cancer</i> , 2005, 104, 561-569.	4.1	106
486	Phase I Study of the Farnesyltransferase Inhibitor BMS-214662 Given Weekly in Patients with Solid Tumors. <i>Clinical Cancer Research</i> , 2005, 11, 4151-4159.	7.0	14

#	ARTICLE	IF	CITATIONS
487	Tumor Growth Inhibition by Simultaneously Blocking Epidermal Growth Factor Receptor and Cyclooxygenase-2 in a Xenograft Model. <i>Clinical Cancer Research</i> , 2005, 11, 6261-6269.	7.0	123
488	Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). <i>Journal of the National Cancer Institute</i> , 2005, 97, 94-102.	6.3	309
489	Activation of Nuclear Factor- $\kappa$ B Contributes to Induction of Death Receptors and Apoptosis by the Synthetic Retinoid CD437 in DU145 Human Prostate Cancer Cells. <i>Cancer Research</i> , 2005, 65, 6354-6363.	0.9	79
490	New Paradigm in Dose-Finding Trials: Patient-Specific Dosing and Beyond Phase I. <i>Clinical Cancer Research</i> , 2005, 11, 5342-5346.	7.0	47
491	The Role of Bisphosphonates in the Management of Advanced Cancer with a Focus on Non-Small-Cell Lung Cancer. <i>Oncology</i> , 2005, 68, 18-22.	1.9	16
492	Chemoprevention of lung cancer: concepts and strategies. <i>Expert Review of Anticancer Therapy</i> , 2005, 5, 549-565.	2.4	4
493	Decoy Receptor 2 (DcR2) Is a p53 Target Gene and Regulates Chemosensitivity. <i>Cancer Research</i> , 2005, 65, 9169-9175.	0.9	73
494	Farnesyltransferase Inhibitor SCH66336 Induces Rapid Phosphorylation of Eukaryotic Translation Elongation Factor 2 in Head and Neck Squamous Cell Carcinoma Cells. <i>Cancer Research</i> , 2005, 65, 5841-5847.	0.9	20
495	The Synergistic Combination of the Farnesyl Transferase Inhibitor Lonafarnib and Paclitaxel Enhances Tubulin Acetylation and Requires a Functional Tubulin Deacetylase. <i>Cancer Research</i> , 2005, 65, 3883-3893.	0.9	101
496	The Role of Bisphosphonates in the Management of Advanced Cancer with a Focus on Non-Small-Cell Lung Cancer. <i>Oncology</i> , 2005, 68, 10-17.	1.9	13
497	O-082 A randomized phase III trial comparing ionafarnib/carboplatin/paclitaxel versus carboplatin/paclitaxel (CP) in chemotherapy-naïve patients with advanced or metastatic non-small cell lung cancer (NSCLC). <i>Lung Cancer</i> , 2005, 49, S30.	2.0	17
498	O-086 A phase III randomized trial of carboplatin/paclitaxel, with or without bexarotene (Targretin®), in chemotherapy-naïve patients with advanced or metastatic non-small cell lung cancer (NSCLC). <i>Lung Cancer</i> , 2005, 49, S31.	2.0	0
499	Activation of Akt and eIF4E Survival Pathways by Rapamycin-Mediated Mammalian Target of Rapamycin Inhibition. <i>Cancer Research</i> , 2005, 65, 7052-7058.	0.9	759
500	GRIM-19 expression and its correlation with clinical outcomes of an induction chemotherapy for patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). <i>Journal of Clinical Oncology</i> , 2005, 23, 5519-5519.	1.6	1
501	A phase II study of lonafarnib (SCH66336) in patients with chemo-refractory advanced head and neck squamous cell carcinoma (HNSCC). <i>Journal of Clinical Oncology</i> , 2005, 23, 5565-5565.	1.6	9
502	Role of cyclooxygenase-2 (COX-2) expression in tumor progression and survival in the squamous cell carcinoma of the head and neck (HNSCC). <i>Journal of Clinical Oncology</i> , 2005, 23, 5508-5508.	1.6	1
503	Chemoprevention of Upper Aerodigestive Tract Cancer. , 2005, , 371-382.		0
504	Chemoprevention in Head and Neck Cancer. , 2005, , 279-303.		0

#	ARTICLE	IF	CITATIONS
505	Novel targeted agents in the treatment of lung cancer. Expert Opinion on Investigational Drugs, 2004, 13, 609-629.	4.1	2
506	Apolipoprotein E and the Risk of Breast Cancer in African-American and Non-Hispanic White Women. Oncology, 2004, 66, 79-93.	1.9	53
507	Early Deaths and Treatment-Related Mortality in Children Undergoing Therapy for Acute Myeloid Leukemia: Analysis of the Multicenter Clinical Trials AML-BFM 93 and AML-BFM 98. Journal of Clinical Oncology, 2004, 22, 4384-4393.	1.6	230
508	Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer. Annals of Oncology, 2004, 15, 1187-1193.	1.2	82
509	Effects of Insulin-like Growth Factor Binding Protein-3 and Farnesyltransferase Inhibitor SCH66336 on Akt Expression and Apoptosis in Non-Small-Cell Lung Cancer Cells. Journal of the National Cancer Institute, 2004, 96, 1536-1548.	6.3	72
510	Emerging drugs for head and neck cancer. Expert Opinion on Emerging Drugs, 2004, 9, 91-104.	2.4	3
511	Protein Farnesyltransferase Inhibitor (SCH 66336) Abolishes NF- $\kappa$ B Activation Induced by Various Carcinogens and Inflammatory Stimuli Leading to Suppression of NF- $\kappa$ B-regulated Gene Expression and Up-regulation of Apoptosis. Journal of Biological Chemistry, 2004, 279, 26287-26299.	3.4	109
512	Farnesyl transferase inhibitors: the next targeted therapies for breast cancer?. Endocrine-Related Cancer, 2004, 11, 191-205.	3.1	33
513	c-Jun NH2-Terminal Kinase-Mediated Up-regulation of Death Receptor 5 Contributes to Induction of Apoptosis by the Novel Synthetic Triterpenoid Methyl-2-Cyano-3,12-Dioxooleana-1,9-Dien-28-Oate in Human Lung Cancer Cells. Cancer Research, 2004, 64, 7570-7578.	0.9	161
514	Expression of Hepatoma-Derived Growth Factor Is a Strong Prognostic Predictor for Patients With Early-Stage Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 2004, 22, 3230-3237.	1.6	109
515	The farnesyltransferase inhibitor lonafarnib induces growth arrest or apoptosis of human lung cancer cells without downregulation of Akt. Cancer Biology and Therapy, 2004, 3, 1092-1098.	3.4	27
516	Use of Replicating Oncolytic Adenoviruses in Combination Therapy for Cancer. Clinical Cancer Research, 2004, 10, 5299-5312.	7.0	147
517	Prognostic Factors in Resected Stage I Non-Small-Cell Lung Cancer: A Multivariate Analysis of Six Molecular Markers. Journal of Clinical Oncology, 2004, 22, 4575-4583.	1.6	137
518	Advances in Chemoprevention of Head and Neck Cancer. Oncologist, 2004, 9, 302-311.	3.7	32
519	Retinoids in Lung Cancer: Friend, Foe, or Fellow Traveler?. Journal of Clinical Oncology, 2004, 22, 3435-3437.	1.6	12
520	Sex differences in survival in non-small cell lung cancer patients 1974-1998. Acta Oncologica, 2004, 43, 57-64.	1.8	51
521	Communicating suffering in primary stage head and neck cancer*. European Journal of Cancer Care, 2004, 13, 53-64.	1.5	28
522	Mechanisms underlying lack of insulin-like growth factor-binding protein-3 expression in non-small-cell lung cancer. Oncogene, 2004, 23, 6569-6580.	5.9	63



#	ARTICLE	IF	CITATIONS
523	Novel agents and incremental advances in the treatment of head and neck cancer. Seminars in Oncology, 2004, 31, 3-10.	2.2	14
524	The care of the lung cancer patient in the 21st century: A new age. Seminars in Oncology, 2004, 31, 11-15.	2.2	43
525	Chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck. Seminars in Oncology, 2004, 31, 809-815.	2.2	31
526	A qualitative study of head and neck cancer. Supportive Care in Cancer, 2004, 12, 338-346.	2.2	21
527	A Phase II study of docetaxel and carboplatin as neoadjuvant therapy for nasopharyngeal carcinoma with early T status and advanced N status. Cancer, 2004, 100, 991-998.	4.1	36
528	Longitudinal study of smoking patterns in relation to the development of smoking-related secondary primary tumors in patients with upper aerodigestive tract malignancies. Cancer, 2004, 101, 2837-2842.	4.1	120
529	Prevention of head and neck cancer: Current status and future prospects. Current Problems in Cancer, 2004, 28, 265-286.	2.0	12
530	Chemoprevention in lung cancer. Current Problems in Cancer, 2004, 28, 287-306.	2.0	3
531	Death Receptor Regulation and Celecoxib-Induced Apoptosis in Human Lung Cancer Cells. Journal of the National Cancer Institute, 2004, 96, 1769-1780.	6.3	240
532	Phase I Study of the Farnesyltransferase Inhibitor Lonafarnib with Paclitaxel in Solid Tumors. Clinical Cancer Research, 2004, 10, 2968-2976.	7.0	80
533	Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: final report. Lung Cancer, 2004, 44, 369-379.	2.0	282
534	p53 Upregulates Death Receptor 4 Expression through an Intronic p53 Binding Site. Cancer Research, 2004, 64, 5078-5083.	0.9	158
535	Chemoprevention of lung cancer. Current Opinion in Pulmonary Medicine, 2004, 10, 279-283.	2.6	27
536	Molecularly Targeted Approaches to the Chemoprevention of Lung Cancer. Clinical Cancer Research, 2004, 10, 4249s-4253s.	7.0	33
537	Definitive treatment of intermediate stage laryngeal squamous cell (SCC/L) cancer with chemotherapy (CT). Journal of Clinical Oncology, 2004, 22, 5533-5533.	1.6	2
538	Prognostic factors in early stage head and neck squamous cell carcinoma (HNSCC) patients in a prospective clinical trial. Journal of Clinical Oncology, 2004, 22, 5515-5515.	1.6	0
539	Sex Differences in Survival in Non-small Cell Lung Cancer Patients 1974-1998. Acta Oncologica, 2004, 43, 57-64.	1.8	12
540	Second primary tumors in patients with upper aerodigestive tract cancers: joint effects of smoking and alcohol (United States). Cancer Causes and Control, 2003, 14, 131-138.	1.8	140

#	ARTICLE	IF	CITATIONS
541	Waldenström's macroglobulinemia with an IgM paraprotein that is both a cold agglutinin and a cryoglobulin and has a suppressive effect on progenitor cell growth. <i>Transfusion</i> , 2003, 34, 910-914.	1.6	12
542	Primary and Secondary Prevention of Non-Small-Cell Lung Cancer: The SPORE Trials of Lung Cancer Prevention. <i>Clinical Lung Cancer</i> , 2003, 5, S36-S40.	2.6	12
543	Mode of action of docetaxel – a basis for combination with novel anticancer agents. <i>Cancer Treatment Reviews</i> , 2003, 29, 407-415.	7.7	192
544	Retinoic Acid Receptor $\alpha$ and Telomerase Catalytic Subunit Expression in Bronchial Epithelium of Heavy Smokers. <i>Journal of the National Cancer Institute</i> , 2003, 95, 165-168.	6.3	20
545	Treatment of Former Smokers With 9-cis-Retinoic Acid Reverses Loss of Retinoic Acid Receptor- $\alpha$ Expression in the Bronchial Epithelium: Results From a Randomized Placebo-Controlled Trial. <i>Journal of the National Cancer Institute</i> , 2003, 95, 206-214.	6.3	86
546	Phase I Clinical and Pharmacology Study of Clofarabine in Patients With Solid and Hematologic Cancers. <i>Journal of Clinical Oncology</i> , 2003, 21, 1167-1173.	1.6	185
547	Replicative Oncolytic Adenoviruses in Multimodal Cancer Regimens. <i>Human Gene Therapy</i> , 2003, 14, 933-946.	2.7	71
548	Selective Serotonin Reuptake Inhibitor-induced Rhabdomyolysis Associated with Irinotecan. <i>Southern Medical Journal</i> , 2003, 96, 1031-1033.	0.7	24
549	Prevention and Early Detection of Lung Cancer. , 2003, , 256-279.		0
550	Progress in Lung Cancer Chemoprevention. <i>Cancer Control</i> , 2003, 10, 315-324.	1.8	17
551	Aerodigestive Tract Chemoprevention Trials and Prevention of Second Primary Tumors. , 2003, , 271-285.		0
552	Chemoprevention of Aerodigestive Tract Cancers. <i>Annual Review of Medicine</i> , 2002, 53, 223-243.	12.2	36
553	Phase II Trial of Docetaxel and Cisplatin Combination Chemotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck. <i>Journal of Clinical Oncology</i> , 2002, 20, 1593-1599.	1.6	78
554	Phase II and Biologic Study of Interferon Alfa, Retinoic Acid, and Cisplatin in Advanced Squamous Skin Cancer. <i>Journal of Clinical Oncology</i> , 2002, 20, 364-370.	1.6	72
555	Safety and Pharmacokinetic Effects of TNP-470, an Angiogenesis Inhibitor, Combined With Paclitaxel in Patients With Solid Tumors: Evidence for Activity in Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2002, 20, 4440-4447.	1.6	98
556	A phase I study of fludarabine combined with radiotherapy in patients with intermediate to locally advanced head and neck squamous cell carcinoma. <i>Radiotherapy and Oncology</i> , 2002, 63, 187-193.	0.6	19
557	Phase II and Biologic Study of Interferon Alfa, Retinoic Acid, and Cisplatin in Advanced Squamous Skin Cancer. <i>Journal of Clinical Oncology</i> , 2002, 20, 364-370.	1.6	129
558	Phase II Trial of Docetaxel and Cisplatin Combination Chemotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck. <i>Journal of Clinical Oncology</i> , 2002, 20, 1593-1599.	1.6	104



#	ARTICLE	IF	CITATIONS
559	Overview of rationale and clinical trials with signal transduction inhibitors in lung cancer. <i>Seminars in Oncology</i> , 2002, 29, 15-26.	2.2	31
560	Randomized phase III study of chemoradiation with or without amifostine for patients with favorable performance status inoperable stage II-III non-small cell lung cancer: Preliminary results. <i>Seminars in Radiation Oncology</i> , 2002, 12, 46-49.	2.2	86
561	Farnesyltransferase Inhibitors: A Promising Future in Cancer Treatment. <i>Clinical Lung Cancer</i> , 2002, 4, 63-64.	2.6	1
562	The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma. <i>Cancer</i> , 2002, 95, 340-353.	4.1	34
563	Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck. <i>Cancer</i> , 2002, 95, 322-330.	4.1	54
564	Chemoprevention of lung cancer. <i>Current Oncology Reports</i> , 2002, 4, 341-346.	4.0	6
565	Chemoprevention of lung cancer: current status and future prospects. <i>Cancer and Metastasis Reviews</i> , 2002, 21, 349-362.	5.9	12
566	Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. <i>Clinical Cancer Research</i> , 2002, 8, 1178-84.	7.0	312
567	Docetaxel for locally advanced or metastatic non-small-cell lung cancer. Current data and future directions as front-line therapy. <i>Oncology</i> , 2002, 16, 53-62.	0.5	2
568	Correlation between insulin-like growth factor-binding protein-3 promoter methylation and prognosis of patients with stage I non-small cell lung cancer. <i>Clinical Cancer Research</i> , 2002, 8, 3669-75.	7.0	111
569	Clinical significance of insulin-like growth factor-binding protein-3 expression in stage I non-small cell lung cancer. <i>Clinical Cancer Research</i> , 2002, 8, 3796-802.	7.0	78
570	A phase II study of STEALTH cisplatin (SPI-77) in patients with advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2001, 34, 427-432.	2.0	123
571	Phase II Trial of Intratumoral Administration of ONYX-015, a Replication-Selective Adenovirus, in Patients With Refractory Head and Neck Cancer. <i>Journal of Clinical Oncology</i> , 2001, 19, 289-298.	1.6	451
572	Multi-Institutional Phase I/II Trial of Oral Bexarotene in Combination With Cisplatin and Vinorelbine in Previously Untreated Patients With Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2001, 19, 2626-2637.	1.6	122
573	Combined Interferon-Alfa, 13-cis-Retinoic Acid, and Alpha-Tocopherol in Locally Advanced Head and Neck Squamous Cell Carcinoma: Novel Bioadjuvant Phase II Trial. <i>Journal of Clinical Oncology</i> , 2001, 19, 3010-3017.	1.6	115
574	Phase I Trial of Oral Green Tea Extract in Adult Patients With Solid Tumors. <i>Journal of Clinical Oncology</i> , 2001, 19, 1830-1838.	1.6	227
575	Epidermal growth factor receptor biology (IMC-C225). <i>Current Opinion in Oncology</i> , 2001, 13, 506-513.	2.4	225
576	Emerging therapies in non-small-cell lung cancer. <i>Annals of Oncology</i> , 2001, 12, 739-744.	1.2	50

#	ARTICLE	IF	CITATIONS
577	Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma. <i>Cancer</i> , 2001, 91, 1316-1323.	4.1	70
578	Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck. <i>Cancer</i> , 2001, 92, 2364-2373.	4.1	46
579	Head and Neck Cancer Committee. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001, 51, 39-43.	0.8	0
580	ZD1839 (Iressa®, GlaxoSmithKline) in Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2001, 3, 27-32.	2.6	13
581	Long-Term Impact of Smoking on Lung Epithelial Proliferation in Current and Former Smokers. <i>Journal of the National Cancer Institute</i> , 2001, 93, 1081-1088.	6.3	87
582	Randomized Phase III Intergroup Trial of Isotretinoin to Prevent Second Primary Tumors in Stage I Non-Small-Cell Lung Cancer. <i>Journal of the National Cancer Institute</i> , 2001, 93, 605-618.	6.3	295
583	Recent advances in the management of squamous cell carcinoma of the head and neck. <i>Expert Review of Anticancer Therapy</i> , 2001, 1, 99-110.	2.4	5
584	Racial Disparity in Survival of Patients with Squamous Cell Carcinoma of the Oral Cavity and Pharynx. <i>Ethnicity and Health</i> , 2001, 6, 165-177.	2.5	65
585	Adenocarcinoma of the lung in young patients. , 2000, 88, 1837-1841.		57
586	Lung cancer chemoprevention. , 2000, 18, 100-105.		24
587	Cellular and humoral immune responses to adenovirus and p53 protein antigens in patients following intratumoral injection of an adenovirus vector expressing wild-type p53 (Ad-p53). <i>Cancer Gene Therapy</i> , 2000, 7, 530-536.	4.6	63
588	Adenovirus-Mediated p53 Gene Transfer in Sequence With Cisplatin to Tumors of Patients With Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2000, 18, 609-609.	1.6	328
589	Retinoic Acid Receptor-Beta as a Prognostic Indicator in Stage I Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2000, 18, 2798-2804.	1.6	86
590	Hypermethylation of the Death-Associated Protein (DAP) Kinase Promoter and Aggressiveness in Stage I Non-Small-Cell Lung Cancer. <i>Journal of the National Cancer Institute</i> , 2000, 92, 1511-1516.	6.3	265
591	A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. <i>Nature Medicine</i> , 2000, 6, 879-885.	30.7	1,037
592	Lung cancer chemoprevention. <i>Journal of Surgical Oncology</i> , 2000, 18, 100.	1.4	1
593	Phase I/II Trial of Radiation With Chemotherapy ± Boost for Advanced Squamous Cell Carcinomas of the Head and Neck: Toxicities and Responses. <i>Journal of Clinical Oncology</i> , 1999, 17, 2390-2390.	1.6	53
594	Adenovirus-Mediated p53 Gene Transfer in Advanced Non-Small-Cell Lung Cancer. <i>Journal of the National Cancer Institute</i> , 1999, 91, 763-771.	6.3	473

#	ARTICLE	IF	CITATIONS
595	Mutagen Sensitivity as a Predictor of Tumor Recurrence in Patients With Cancer of the Upper Aerodigestive Tract. Journal of the National Cancer Institute, 1998, 90, 243-245.	6.3	36
596	Autofluorescence Bronchoscopy in the Detection of Squamous Metaplasia and Dysplasia in Current and Former Smokers. Journal of the National Cancer Institute, 1998, 90, 991-995.	6.3	112
597	Phase II Trial of Recombinant IFN- $\gamma$ 2a with Etoposide/Cisplatin Induction and Interferon/Megestrol Acetate Maintenance in Extensive Small Cell Lung Cancer. Journal of Interferon and Cytokine Research, 1998, 18, 241-245.	1.2	6
598	Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma.. Journal of Clinical Oncology, 1998, 16, 1325-1330.	1.6	104
599	Molecular Epidemiology and Retinoid Chemoprevention of Head and Neck Cancer. Journal of the National Cancer Institute, 1997, 89, 199-211.	6.3	104
600	Clonal Genetic Alterations in the Lungs of Current and Former Smokers. Journal of the National Cancer Institute, 1997, 89, 857-862.	6.3	385
601	CHEMOPREVENTION OF RESPIRATORY TRACT CANCER. Hematology/Oncology Clinics of North America, 1997, 11, 387-408.	2.2	7
602	New Directions in Lung Cancer: Chemoprevention. Seminars in Respiratory and Critical Care Medicine, 1996, 17, 323-334.	2.1	1